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ABSTRACT 
The aim of this study was to determine the influence of probenecid on the urinary excretion 
of anabolic-androgenic steroids. Androsterone is an endogenous steroid and since it is 
excreted in high concentrations in urine, it was used as a representative of anabolic steroids. It 
was also used because it would be unethical to give anabolic-androgenic steroids to healthy 
volunteers just to study the influence of probenecid on the excretion of anabolic steroids. 
A literature survey of the relevant publications reveals a lack of information regarding the 
influence of probenecid on the urinary excretion of anabolic steroids as well as endogenous 
steroids. A pilot study performed at the F ARMOVS Research Centre, Department of 
Pharmacology, Bloemfontein suggested a significant decrease on the urinary excretion of 
androsterone after the intake of probenecid. 
Twenty (20) healthy, male vo lunteers participated in an open, single-dose, randomised, two 
way, cross-over study with a drug-free interval of 7 days between treatment phases. Each 
subject received each of the following 2 treatments once in a randomised order: 
Treatment A: Placebo (control phase) + 200ml water. 
Treatment B: 4 x 500mg Probenecid tablets (Benemid®) + 200ml water. 
On the profile days (Day I and 8), the trial medication was taken at 08:00 with 200ml tap 
water. All subjects were required to take 200ml water hourly for the first four hours after drug 
administration. After administration urine collections were made at predetermined intervals 
over a peroid of 48 hours for the determination of androsterone and probenecid 
concentrations. 
Androsterone was quantified using a gas chromatograph-mass spectrometric method. The 
results showed that the lowest excretion of androsterone was found between 2 - 3 hours after 
administration of probenecid. A statistically significant decrease in the excretion rate of 
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androsterone was seen from 2 to 8 hours after administration of a single dose of probenecid 
(4 x 500mg). The mean androsterone excretion rate for all fractional collection intervals in 
this period (1 - 2 h, 2 - 3 h, 3 - 4 h, 4 - 6 h, 6 - 8 h) were between 56% and 70% lower 
following administration of Benemid® compared to placebo. High doses of probenecid inhibit 
the urinary excretion of androsterone and therefore it will also inhibit the excretion of other 
anabolic steroids excreted as glucuronides in urine. Since the concentration of exogenous 
anabolic steroids in urine is usually very low, probenecid can decrease their concentration to 
below the limit of detection. Thus, probenecid can be used as a masking agent for the 
excretion of anabolic steroid glucuronides. 
This inhibition of the renal excretion of anabolic steroids by probenecid represents a 
manipulation of the urine sample in doping control and therefore probenecid was banned by 
the Medical Commission of the International Olympic Committee. 
III 
-,... • • ':- t"-
I t'lt; , .. .. ,. . (_ . ;~ TV 
OF 'j HE 
- 6 ~ tI' ZDDI 
TECHNlKON 
FREE STATE 
© Central University of Technology, Free State
OPSOMMm6 
Die doel van hierdie studie was om ondersoek in te stel na die invloed van probenesied op die 
urinere uitskeiding van anaboliese sterolede. Aangesien androsteroon, 'n endogene steroled, 
in hoe konsentrasies uitgeskei word, is dit as verteenwoordigend van die anaboliese sterolede 
gebruik. Hierdie benadering is gevolg omdat dit oneties sou wees om anaboliese sterolede aan 
gesonde vrywilligers toe te dien bloot om die invloed van probenesied op die uitskeiding 
daarvan te bestudeer. 
'n Literatuuroorsig van toepaslike publikasies toon 'n gebrek aan inligting oor die invloed 
van probenesied op die urinere uitskeiding van anaboliese sterolede asook endogene 
sterolede. 'n Loodsstudie, wat by die FARMOVS Navorsingssentrum, Departement 
Farmakologie, Bloemfontein uitgevoer is, het 'n betekenisvolle afname in urinere uitskeiding 
van androsteroon aangetoon na inname van probenesied. 
Twintig (20) gesonde manlik vrywilligers het aan 'n oop, enkel dosering, gerandomiseerde, 
tweerigting, oorkruis studie deelgeneem met 'n uitwas periode van 7 dae tussen 
behandelingsfases. Elke vrywilliger het elk van die volgende twee behandelings eenmalig 
ontvang op ' n ewekansige volgorde: 
Behandeling A: Plasebo (kontrole rase) + 200ml water 
Behandeling B: 4 x 500mg probenesied tablette (Benemied@) + 200ml water 
Op profieldae (Dag 1 en 8) is proefinedikasie om 08:00 geneem met 200ml kraanwater. Van 
elke vrywilliger was verwag om daarna 200ml water uurliks vir die eerste vier uur te neem. 
Na geneesmiddel toediening is urine in fraksies versamel oor 'n tydperk van 48 uur vir die 
bepaling van androsteroon en probenesied konsentrasies. 
Androsteroon is bepaal deur 'n gaschromatografiese-massa spektrometriese metode. Die 
resultate toon dat die laagste uitskeiding van androsteroon tussen 2 - 3 uur na toediening van 
IV 
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probenesied was. 'n Statisties betekenisvolle verrnindering in die uitskeidingstempo van 
androsteroon kon tussen 2 en 8 uur waargeneem word. Die gemiddelde androsteroon 
uitskeidingstempo vir al die fraksionele versamelintervalle in hierdie tydperk (I - 2h, 2 - 3h, 
3 - 4h, 4 - 6h, 6 - 8h) was tussen 56% en 70% laer na die inname van Benemid® in 
vergelyking met plasebo. Aangesien hoe doserings probenesied die urinere uitskeiding van 
androsteroon onderdruk kan dit vetwag word dat dit ook die uitskeiding van ander anaboliese 
steroiede, wat as glukuroniedes uitgeskei word, sal onderdruk. Die konsentrasie van eksogene 
anaboliese steroiede is gewoonlik baie laag en dus kan probenesied hulle konsentrasie verlaag 
tot onder die deteksie limiet sodat hulle nie aangetoon kan word nie. Probenesied kan dus 
gebruik word as 'n maskeerrniddel vir die uitskeiding van anaboliese steroied glukuroniedes. 
Hierdie onderdrukking van die renale uitskeiding van anaboliese steroiede deur probenesied 
word beskou as manipulasie van die urierunonster. Gevolglik het die Mediese Kommissie van 
die Intemasionale Olimpiese Komitee probenesied as 'n verbode middel in sport verklaar. 
v 
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INJTRODlJCTION 
A literature survey of the relevant publications reveals a lack of infonnation regarding the influence of probenecid on the urinary excretion of drugs in general and anabolic 
steroids in particular. 
Probenecid is a uricosuric agent used in chronic gout to reduce the incidence and severity of 
attacks. Probenecid also reduces the renal tubular excretion of many other drugs, thereby 
increasing their plasma concentrations, and has therefore been used as an adjunct to 
antibacterial therapy (Reynolds et at., 1996). 
After oral intake, probenecid is rapidly absorbed from the gastro-intestinal tract and is 
extensively bound to plasma proteins (85 to 95%) (Reynolds et at., 1996). Probenecid is 
almost completely metabolised in the liver and about 90% is excreted in the urine in the fonn 
of metabolites during the first 48 hours (Moffat et at., 1986). 
Adverse events most commonly experienced during treatment with probenecid include 
headache, nausea and vomiting, dizziness, flushing, skin rashes and urinary frequency 
(Reynolds et at., 1996). 
The oral fonnulation of probenecid (Benemid®) is tablets containing 500mg probenecid. It is 
usual to start treatment for gout with oral doses of 250mg twice daily, increased after a week 
to 500mg twice daily, if the therapeutic effects are unadequate followed by 500mg increments 
every 4 weeks up to 2g daily. The usual dosage for reducing tubular excretion of penicillins 
and cephalosporins is 500mg four times daily (Reynolds et at., 1996). 
In 1994, a pilot study was conducted with five healthy male volunteers at the Department of 
Phannacology, University of the Orange Free State, to detennine the influence of probenecid 
on the urinary excretion of androsterone. In this cross-over study doses of 500, 1000 and 
2000mg were administered and it led to a decrease of urinary androsterone as illustrated in 
Figure 1.1. 
2 
© Central University of Technology, Free State
FARMOVS 9/ 94 
URINARY ANDROSTERONE CONCENTRATION 
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Figure 1.1 Graphic representative of mean urinary androsterone concentration (~glml) 
(n=5) against time (h) after a single administration of 500, 1000 and 2000mg 
probenecid (Benemid®) (FRM 9/94). 
The use of probenecid in sport was first detected in 1987 in a routine control test of 5 athletes. 
In addition to the presence of probenecid unusually low concentrations of endogenous 
steroids in the urine samples were observed. The mean of the urinary androsterone 
concentration of the 5 athletes was 34nglml whereas the normal concentration of 
androsterone in urine of athletes ranges from 375nglml to 5323nglml. 
Probenecid [p-(dipropylsulphamoyl) benzoic acid] occupies a central place in the field of 
organic anion transport because of its inhibitory potency as a classical competitive inhibitor 
of organic acid transport. Since most of the anabolic steroids, as well as their metabolites, are 
excreted in urine as their glucuronides, one may expect that probenecid inhibits the renal 
excretion of anabolic steroids. Therefore, competitors in sport taking exogenous anabolic 
steroids could use probenecid as a masking agent for the excretion of these compounds. 
Androsterone is an endogenous steroid and since it is excreted in high concentrations in urine, 
it was used as a representative of anabolic-androgenic steroids in this study. Androsterone 
3 
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was also used because it will be unethical to give anabolic steroids to healthy volunteers just 
to study the influence of probenecid on the excretion of anabolic steroids. 
The results of the pilot study necessitate a follow-up study with a sufficient number of 
volunteers to obtain statistical proof of the extent of the suppression of androsterone excretion 
by probenecid. 
4 
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Probenecid is the classical competitive inhibitor of organic acid transport in the kidney and other organs. There are two primary clinical uses for probenecid: as a uricosuric 
agent in the treatment of chronic gout and as an adjunct to enhance blood levels of antibiotics. 
Most of the drug-drug interactions involving probenecid are due to an effect on the kidney-
block of transport of acidic drugs. Similarly probenecid affects the tubular secretion of a 
number of acidic endogenous substances by the kidney (Cunningham et aI., 1981). 







(Source: Moffat et aI., 1986; 923) 







A white crystalline powder with a melting point of 198° 
to 200°C. Practically insoluble in water; slightly soluble 
in ethanol and acetone; soluble in chloroform. 
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A white crystalline powder with a melting point of 
185°C. Practically insoluble in water; soluble in 
ethanol, ether and in most organic solvents. 
2.2 PHARMACOKINETIC PROPERTIES 
Probenecid is highly lipid-soluble; Kp (chloroform/0.15 M HCI) > 2000. The pKa of 
probenecid is 3.4 (aqueous medium) and 5.8 (aqueous-methanol). The binding of probenecid 
to human albumin and plasma is high (range of 83 to 95% for concentrations of 20 -
1761!glml respectively); the binding to human globulins is lower (28 - 33%). Probenecid 
exhibits type I binding spectra when mixed with rat liver micorsomal fractions (Cunningham 
etal.,1981). 
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2.2.1 ABSORPTION 
Absorption of probenecid following oral administration (0.5 to 2g, as free acid in gelatin 
capsules or as tablets) is rapid with peak concentrations occurring in 1 to 5 hours 
(Cunningham et al., 1981 , Selen et al., 1982). Urinary elimination (>80% in 40 hours) of 14C 
following oral administration of 14C-probenecid further indicates completeness of absorption. 
It is to be noted that in children, peak plasma levels following oral administration on 
probenecid (2.5mglkg) occur in 3 to 9 hours . The peak action (as determined by the effect on 
penicillin plasma levels) after an oral dose of probenecid occurs at about 2 hours and the 
action lasts for about 8 hours (Cunningham et aI., 1981). 
2.2.2 DISTRIBUTION 
After intravenous administration, probenecid distributes rapidly with an apparent volume of 
distribution (Vd) of about llL. Cunningham et al., (1981) published the following 
pharmacokinetic parameters of probenecid in patients: 
. Table 2.1 Pharmacokinetic parameters of probenecid in patients . 
PATIENT 
WEIGHT IV DOSE tYl Vd K.I' Cltotal' 
(kg) (g) (b) (Llkg) (b-I) (mllmin) 
1 73 2.0 12 0.162 0.059 11.6 
1 73 0.5 8 0.128 0.087 13.5 
2 68 2.0 6 0.137 0.12 17.9 
2 72 0.5 , 0.122 0.23 33 .8 .> 
3 76 2.0 6 0.175 0.12 25.5 
4 76 0.5 4 0.173 0.17 37.3 
I~I = rate constant of elimination from plasma. 
2Cltotal = total body clearance. With normally acid urine, the renal clearance of probenecid is about 1 to 2 
mVmin; faecal excretion is low «20% of dose). Thus, metabolism accounts for about 90% of the total body 
clearance of probenecid. 
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Following oral administration (500mg, q 6h) for 4 weeks, the mean plasma level of 
probenecid was 22.5flglml (of n = 19 patients). The drug binds extensively to plasma 
proteins. In man, probenecid may inhibit the efflux of endogenous compounds and co-
administered drugs from the eye. The kidney, and especially renal tubules, may accumulate 




In man, the biotransformation of probenecid involves oxidation of alkyl side chains (about 
70%) and glucuronide conjugation (about 20%). Cunningham et al., (1 981) published the 
following metabolism of probenecid: 
"" 
"")-0-10 r f ~ _ ) 
- 8 ""' CH, 
Figure 2.1 Metabolism of probenecid (Cunningham et ai., 1981). 
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The concentrations of oxidised metabolites are much lower (about 10% of the circulating 
dose) than the parent drug in human plasma. The metabolites have lower binding (59 to 81%) 
to plasma proteins and lower lipid solubility than probenecid; this accounts for the rapid 
clearance of probenecid metabolites. Self-stimulation of probenecid metabolism has been 
reported in animals. Although the fate of probenecid in man appears to be totally explained 
by side chain metabolism, glucuronide conjugation and excretion of the unchanged drug, the 
possibility of aromatic ring oxidation was investigated (Cunningham et at., 1981). 
2.2.3.2 ANDROSTERONE 
Androsterone is a naturally occurring androgen which may be isolated from male urine. It is a 
major metabolite of testosterone (Moffat et at., 1986). In contrast to the diol metabolites of 
testosterone with a 17P-hydroxy structure (D-ring), the main metabolites, androsterone (3a-
hydroxy-5a-androstane-17-one) and etiocholanolone (3a-hydroxy-5p-androstane-17-one), 
have a 17-keto-D-ring structure (Schanzer et at., 1997). Schanzer et at., (1997) published the 
following metabolism of testosterone: 




5a-androstanediol androsterone SI),_androstanediol etiocholanolone 
Figure 2.2 Metabolism of testosterone (Schanzer et at., 1997). 
10 
© Central University of Technology, Free State
2.2.4 HALF-LIFE 
In most individuals the half-life of probenecid following a 2g dose (oral or intravenous) 
ranged between 6 to 12 hours. In man, dose dependence was observed in the elimination half-
life given intravenously or orally. The plasma concentration decline being rapid at lower 
doses (half-life: 2 to 6 hours after 0.5 to 19 and 4 to 12 hours after 2g) (Cunningham et ai., 
1981 ). 
2.2.5 ELIMINATION 
After a single doses of 0.5 to 2g of probenecid, 75 to 88% of the drug was recovered in urine 
in 4 days with only a small amount (5 to 11%) as the intact drug. The major metabolic 
product was excreted as probenecid-acyl glucuronide (16 to 47%) while the remainder of the 
metabolised drug was recovered in approximately equal amounts of the other metabolites 
(mono N-propyl, secondary alcohol, carboxyl and primary alcohol) in the free form 
(Cunningham et ai., 1981). Cunningham et ai., (1981) found the renal clearance of 
probenecid to be independent of dose but dependent on the pH and flow rate of urine. 
2.3 PHARMACODYNAMICS 
Probenecid is actively secreted into the kidney tubules, but is efficiently reabsorbed into the 
peri tubular capillaries, and only a small fraction of the drug is cleared by this route (Selen et 
ai., 1982). It seems important that sufficiently high doses of probenecid must be used to 
produce a nearly complete blockade of transport. Probenecid is a competitive inhibitor of 
active transport processes by which acidic metabolites of noradrenaline, dopamine and 
serotinin are removed from the brain and cerebrospinal fluid. This active transport process is 
similar to that found in the kidney. The interaction of probenecid with drugs that influence 
urate transport are of particular interest. They suggested that two separate and simultaneous 
mechanisms are involved when antagonism of uricosuric activity occurs a) competition for 
transport, decreasing delivery of the second drug to the active site, and b) inhibition of urate 
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secretion. Other interactions of drugs with probenecid possibly involve competition for 
binding to plasma and tissue proteins, as well as effects on microsomal drug metabolising 
enzymes (Cunningham et aI., 1981). 
2.3.1 PROBENECID AS A URICOSURIC AGENT 
The uricosuric activity of probenecid was discovered in 1950 and the drug found to be of 
value in the treatment of chronic gout. At a dose of 1 to 2g of probenecid, uric acid clearance 
increases of 4- to 6-fold were found in man (Dayton et al., 1963; Sirota et al.. 1952). The 
contribution of the metabolites of probenecid to the overall uricosuric activity of the drug is 
probably less significant than that of probenecid, due to the high renal clearance and 
elimination half-life of metabolites as shown in dogs (Cunningham et aI., 1981). 
2.3.2 PROBENECID INTERACTION WITH ANTIDIOTICS 
The co-administration of probenecid with a number of acidic compounds, particularly 
antibiotics, generally causes an increase in peak plasma concentrations and half-life and 
decrease in distribution half-life and urinary excretion of these compounds. The earliest 
clinical application of probenecid was as an adjunt to high dose penicillin therapy and in the 
treatment of turberculosis with para-aminosalicylic acid. The latter antibiotic is extensively 
conjugated in the liver with glycine; the conjugate is therapeutically active and is rapidly 
excreted by the kidney with renal clearance approximating that of renal blood flow. More 
detailed clinical studies of blood levels and excretion patterns of ampicillin, nafcillin and 
cephaloridine with and without administration of probenecid, showed that the action of 
probenecid at the renal level was not sufficient to account for several fold serum level 
elevations encountered (Cunningham et al .. 1981). 
Cunningham et al.. (1981) also suggested that probenecid causes a significant decrease in the 
distribution volume of the antibiotic. Only in this way could one rationalise the marked effect 
on renal retention. This decrease in distribution volume would indicate that probenecid 
probably competes for drug binding sites in the kidney, liver and other tissues and/or blocks 
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transport of antibiotics into tissues. Although this hypothesis has not been fully tested, 
probenecid continues to be co-administered with many antibiotics. The tacit assumption is 
that enhanced tissue levels will follow when plasma levels are increased by whatever means. 
Probenecid has also been co-administered with certain antibiotics of short biological half-life 
(cefoxitin, cefazolin and cephalothin) to prolong their plasma concentrations so that patients 
may be given doses of the antibiotic less frequently (8 hourly or longer). The possibility that 
target tissues may be exposed to lower concentrations of antibiotic than might be predicted 
from blood levels (when probenecid is concomitantly administered) has been pointed out by 
Cunningham et al. It has been shown, however, that probenecid does not affect the entry of 
antibiotics into fibrin clots in vitro (Cunningham et ai., 1981). 
2.3.3 PROBENECID INTERACTION WITH FUROSEMIDE 
Probenecid decreased the oral clearance, the renal clearance and the calculated non-renal 
clearance of furosemide, which may indicate that active secretion into bile, or the rate of 
hepatic glucuronidation is decreased. All three clearance parameters were reduced to 
approximately 35% of their baseline value. Impaired kidney function will reduce the renal 
secretion of both parent drug and conjugate. Reduction of kidney function by probenecid did 
not affect the percentage of the dose recovered as furosemide glucuronide; however, it slowed 
the elimination processes (Vree et ai., 1995). 
2.3.4 PROBENECID INTERACTION WITH DYPHYLLINE 
Dyphylline has been shown to be primarily eliminated by the kidneys, with 80 to 85% 
appearing unchanged in the urine. The kinetic parameters of dyphylline elimination in control 
subjects clearly implicate both active secretion and glomerular filtration. In spite of the 
concomitant use of probenecid, it is likely that a significant fraction of a dyphylline dose is 
still eliminated by the kidneys in unchanged form. Further studies on the interaction of 
probenecid and dyphylline are necessary to determine the clinical utility of concomitant 
dyphylline - probenecid use (May and Jarboe, 1983). 
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2.3.5 PROBENECID INTERACTION WITH ANABOLIC STEROIDS 
The fact that the renal excretion of androsterone can be depressed by probenecid confirms the 
tubular secretion of this steroid, since probenecid is known to block the renal tubular 
secretion of compounds such as para-aminosalicylic acid and penicillin. The renal clearance 
of androsterone in man has been shown to be much greater than that of 
dehydroepiandrosterone. This explains the preponderance of dehydroepiandrosterone m 
human plasma on the basis of renal factors rather than on the basis of an inordinately high 
production of this steroid. The rapid renal clearance of androsterone accounts for its greater 
concentration in human urine and indicates that its over-all production is greater than that of 
dehydroepiandrosterone in man. The renal excretion of androsterone is inversely proportional 
to the elevated blood levels produced by its administration, and is inhibited by probenecid; 
therefore, androsterone is eliminated by tubular secretion rather than glomerular filtration. It 
appears unlikely that dehydroepiandrosterone is reabsorbed by the renal tubules after 
significant glomerular filtration, since its urinary excretion is not enhanced by probenecid. 
The renal clearance of beta-cortolone was also determined. Administration of this substance 
appeared to diminish the plasma levels of Porter-Silber chromogens in a single experiment 
(Bongiovanni and Eberlein., 1957 ). 
Gardner et ai., (1951) reported that Benemid in doses of 2g per day per adult produced 
approximately 50% decrease in urinary excretion of 17-ketosteroids. Urinary 11-
oxycorticosteroids did not appear to be affected by Benemid. 
2.4 ADVERSE A VENTS AND ABUSE OF PROBENECID 
Probenecid is generally well tolerated, though nausea, vomiting, anorexia, headache, sore 
gums, flushing, dizziness and urinary frequency may occasionally occur. Hypersensitivity 
reactions, with fever, dermatitis, prutitus, urticaria and rarely anaphylaxis have occurred. 
When used in chronic gout, probenecid may precipitate an acute attack, and renal calculi or 
renal colic with or without haematuria, may occur. It has been alleged that some athletes 
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using banned anabolic steroids have been taking probenecid in an attempt to inhibit the 
urinary excretion of steroid metabolites in order to avoid detection by urine screening tests 
(Reynolds et a/., 1996). 
2.5 ANALYTICAL METHODS 
2.5.1 PROBENECID 
Conway and Melethil, (1975) developed a gas chromatograhic method for the detection of 
probenecid and its metabolites in biological fluids. The method involves direct extraction of 
the free acids from acidified urine by methylene dichloride or acid hydrolysis of conjugated 
metabolites prior to extraction, addition of N,N-dibenzyl-(2,5-dimethylbenzenesulfonamide) 
as an internal standard, followed by gas chromatography using flame ionization detection. 
Hekman et ai., (1980) felt the need to develop a rapid and sensitive quantitative method for 
the detection of probenecid in plasma and urine, because 'of the various older 
spectrophotometric methods . that have been reported lack the required sensitivity and 
specificity. They used high performance liquid chromatography and the chromatography is 
performed in a soap chromatography mode using a Cg hydrocarbon stationary phase. As 
internal standards the diethyl analog (diethylsulfamoyl benzoic acid) and the diisobutyl 
analog (diisobutylsulfamoyl benzoic acid) of probenecid were applied. This method of 
probenecid analysis was successfully applied to pharmacokinetic studies. 
Campins-Falc6 et ai., (1994) used a column-switching technique for the screemng of 
probenecid in urine samples. This method was based on high performance liquid 
chromatography using column-switching and a pre-column for the on-line sample cleanup 
and enrichment. Untreated urine samples were directly injected and the pre-column flushed 
with water to eliminate polar matrix components. Th etaod-i-s-seleGt1,ve-aa sensitive 
THIS BOOK IS 
enough to detect probenecid in urine and the proposed cp~~:~J":l,tf,1iiq.~:t~sfef1 leads to a 
considerable saving of both chemicals and time. 
15 
- G SEP 2001 
TECHNIKON 
FREE STATE 
© Central University of Technology, Free State
2.5.2 ANDROSTERONE 
The first comprehensive and sensitive gas chromatographic-mass spectrometric screerung 
procedure for the detection of anabolic as well as endogenous steroids was developed by 
Donike (Donike et ai. , 1993). 
Masse et ai., (1989) also developed a gas chromatographic-mass spectrometric method for 
anabolic and endogenous steroids in urine. This method involved solid phase extraction with 
5a-androstan-17-one as external standard. For the specific purpose of gas chromatographic-
mass spectrometric screening, where specificity and sensitivity were the major analytical 
requirements, trimethylsilyl enol-trimethylsilyl ether derivatives were prepared using 
trimethylsilyl iodide as catalyst. 
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STUDY' METHODS 
T7his study was conducted as an open, single-dose, randomised, two way, cross-over study with a drug-free interval of 7 days between treatment phases. Subjects were randomly 
assigned to treatment order. 
3.1 STUDY POPULATION 
3.1.1 NUMBER OF SUBJECTS 
Twenty (20) healthy, male subjects who fulfilled the inclusion criteria (Section 3.1.2), did not 
meet any of the exclusion criteria (Section 3.1.3), and who gave written informed consent, 
entered the study. Subjects were recruited from the Department of Pharmacology. 
3.1.2 INCLUSION CRITERIA 
a) Healthy male volunteers between 18 and 45 years of age. 
b) Body weight within 10% of the ideal weight according to the Body Mass Index (BMI) 
(Appendix 2). 
c) Findings within the range of clinical acceptability in medical history and physical 
examination and laboratory results within the nonnal ranges for the relevant 
laboratories, unless the clinical investigator considers the degree of abnormality to be 
clinically irrelevant for the purpose of the study. 
d) Normal vital signs or abnormalities which the clinical investigator does not consider a 
disqualification for participation in the study. 
e) Willing to undergo pre- and post-study medical examinations and laboratory 
investigations. 
f) Subjects willing and able to sign voluntarily an informed consent form at the initial 
screening visit. 
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3.1.3 EXCLUSION CRITERIA 
a) Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional 
or intellectual problems likely to limit the validity of consent to participate in the 
study, or the ability to comply with protocol requirements. 
b) Abuse or regular use of alcohol or medication, use of any medication up to 2 weeks, 
or participation in another study with an experimental drug witin 8 weeks before the 
study. 
c) Treatment within the previous 3 months with any drug with a well-defined potential 
for toxicity in a major organ or system (for example, chloramphenicol, which may 
cause bone marrow suppression). 
d) A major illness during the 3 months before commencement of study-related 
procedures. 
e) History of hypersensitivity to the study drug or any related drug. 
f) History of presence of gastro-intestinal, liver, or kidney disease, or other conditions 
known to interfere with the absorption, distribution, metabolism or excretion of drugs. 
g) History of bronchial asthma. 
3.1.4 W ITHDRAWAL CRITERIA 
a) Subjects not wishing to continue with the study, irrespective of the reason. 
b) Unwanted effects from the study drug. 
c) Abnormal findings in laboratory investigations of physical examinations. 
d) Intercurrent illness requiring medication or invalidating data. 
e) Protocol violation by SUbjects. 
f) Pathologically raised body temperature on clinic days. 
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3.1.5 PRE-STUDY SCREENING 
Subjects were examined within 2 weeks before the study and assessed for their ability to 
participate. The examinations and investigations included: 
(i) Medical history and physical examination. 
(ii) Measurements of height and body mass. 
(iii) Haematology: leucocytes, erythrocytes, haemoglobin, haematocrit, platelets, 
neutrophils, eosinophils, lymphocytes. 
(iv) Clinical chemistry: potassium, urea, creatinine, uric acid, calcium, protein, albumin, 
total bilirubin, ALP, GGT, AST, ALT, glucose. 
(v) Urinalysis (MuItistix@ SG): pH, specific gravity, protein, glucose, ketones, 
bilirubin, blood, urobilinogen. 
3.1.6 POST-STUDY CLINICAL AND SAFETY EVALUATIONS 
Haematological and clinical investigations were repeated within 72 hours of completion of 
the final phase of the study. 
3.1.7 RESTRICTIONS ON SUBJECTS 
With the exception of the study drugs, all subjects had to refrain from taking any medicines, 
including those sold over the counter, for 2 weeks before the study started and for the 
duration of the study (Section 3.1.3). Ingestion of foods and beverages containing alcohol or 
caffeine, as well as hazardous, strenuous or athletic activities were not permitted for 24 hours 
before and until 24 hours after drug administration on clinic days. Subjects were, as far as 
possible, recruited from members of the Department of Pharmacology, who proceeded with 
their normal daily work after drug administration in the F ARMOVS Research Centre. Food 
and fluid intake was standardized to minimize variations within and among individual 
subjects until 13:00 on the profile day. Subjects received 200ml water hourly for the first four 
hours after drug administration. 
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3.1.8 DROP-OUTS 
One subject failed to complete the study. A total of nineteen (19) volunteers completed the 
study. 
3.2 STUDY DRUGS 
3.2.1 TREATMENTS AND DOSAGES 
Each subject received each treatment once. Subjects were allocated to treatment order 
according to the randomisation schedule (Appendix 1). 








Placebo (control phase) 
Probenecid 
Benemid® 
Logos Pharmaceuticals [LOGOS] 
Tablets containing 500mg probenecid 
2000mg once 
3.2.2 DOSAGE INSTRUCTIONS 
After an overnight fast of at least 10 hours, subjects received the relevant product (4 tablets) 
with 200ml tap water according to the randomisation schedule. Dosing was staggered at 
specific intervals, starting at 08:00 with the first subject. 
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3.2.3 RANDOMISATION SCHEDULE 
The randomisation schedule was generated USIng RANDOM (Version 1.1), a locally 
developed program written in MS FORTRAN (Version 5.1) which runs under the MS-DOS 
operating system and is included in Appendix 1. 
3.2.4 SUPPLY, STORAGE AND DISPENSING 
All study drugs were stored in a limited access area in which the temperature was regulated. 
Administration of the drug on clinic days was supervised by the clinical investigator. 
3.2.5 PACKAGING, LABELLING AND RAL"IDOMISA TION 
Packaging, labelling and randomisation of the study was carried out by the pharmacist from 
F ARMOVS Research Centre. Each single dose was retained in a separate container with a 
label indicating the study number, subject's number, treatment and treatment phase. 
3.3 STUDY PERFORMANCE 
The study was carried out in the FARMOVS Research Centre, University of the Orange Free 
State, Bloemfontein, Republic of South Africa and was designated as FARMOVS 9/96. 
Subjects received detailed instructions of the study performance, restrictions, obligations, 
remunerations and possible adverse events that may be experienced as a result of taking the 
study drugs. 
3.3.1 TREATMENT PHASES 
The study consisted of 2 treatment phases. Each included a single-dose run-in period of 2 
days (Days I and 8 - profile days). 
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Run-in peroid (profile days) 
During the run-in peroids, placebo or Benemid® (2000mg), as laid out in the randomisation 
plan, was administered to subjects at 08 :00, swallowed with 200ml tap water at room 
temperature. 
Subjects were, as far as possible, recruited from members of the Department of 
Pharmacology, who proceeded with their normal daily work after drug administration in the 
F ARMOVS Research Centre. Food and fluid intake were standardized to minimize variations 
within and among individual subjects until 13:00 on the profile day, thereafter food and fluid 
intake was allowed ad libitum. Subjects received 200ml water hourly for the first four hours 
after drug administration. 
Urine sampling 
Urine was collected in large labelled plastic bottles. Immediately before drug administration, 
subjects emptied their bladders completely at completion of the -12-0 interval. Urine 
collections were made during the following intervals before and after drug administration: 
-12-0,0-1 , 1-2,2-3,3-4,4-6,6-8,8-12,12-24,24-30, 30-36 and 36-48 hours (12 samples per 
subject per treatment phase). The actual urine sampling times were documented in the case 
report forms (CRF's). From each fraction the pH, SG and creatinine were measured. The 
volumes of collected urine were recorded within 30. minutes and 2 aliquots (20ml) of each 
urine sample were transferred to labelled tubes. All samples were handled at room 
temperature and stored at -20cC until probenecid and androsterone were assayed. 
3.3.2 SPECIAL INVESTIGATIONS 
All clinical chemistry investigations were performed in F ARMOVS Research Centre and 
haematological investigations in the Department of Haematology, University of the Orange 
Free State, Bloemfontein, Republic of South Africa. 
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3.4 MANDATORY CONSIDERATIONS 
3.4.1 ETmCAL AND INSTITUTIONAL REVIEW 
This project was reviewed and approved by a Faculty Research Committee at the Technicon 
Free State. Approval by the Ethics Committee of the Faculty of Health Sciences of the 
University of the Orange Free State was given before commencement of the study-related 
procedures. 
3.4.2 SUBJECT INFORMATION AND INFORMED CONSENT 
Before the study, the nature, purpose and risk of the research involved were explained to all 
subjects. They were informed that they may withdraw from the screening procedures or the 
study-specific procedures at any time and for any reason. They signed both F ARMOVS 
informed consent forms in the presence of the clinical investigator and a witness after 
sufficient time for deliberation had been provided. 
3.4.3 ADVERSE EVENTS/ SERIOUS ADVERSE EVENTS 
Clinical adverse events or serious clinical adverse events are any undesirable expenence 
occuring in a subject during a clinical study, whether or not it is thought to be associated with 
the study drug. These include illnesses, subjective and objective signs or symptoms 
(including important abnormal laboratory values as well as significant shifts from baseline 
within the range of normal, which the investigator considers to be clinically important), 
which have appeared or worsened during the course of a study. 
3.4.4 GOOD CLINICAL PRACTICE/QUALITY ASSURANCE 
The conduct of the study conformed with the recommendations for clinical studies in man as 
set out in the 1989 Hong Kong Revision of the "Declaration of Helsinki" (Appendix 4), the 
local legal requirements, and in accordance with the guidelines on "Good Clinical Practice for 
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Trials on Medicinal Products in the European Community" (CPMP Working Party on 
Efficacy of Medicinal Products, 1990). Internal auditing by the Quality Control and Quality 
Assurance officers of F ARMOVS was carried out at all stages of the study. A Quality 
Assurance Statement is included in Appendix 5. 
3.4.5 INDEMNITY 
Insurance was arranged to cover the subjects in the event of death or any deterioration in 
health or well-being caused by participation in the study. The certificate of insurance is 
presented in Appendix 3. 
3.4.6 CONFIDENTIALITY 
All information obtained during the conduct of the study with respect to the subject's state of 
health is regarded as confidential. An agreement for disclosure of any such information was 
obtained in writing and was included in the informed consent form. 
3.4.7 REMUNERATION OF SUBJECTS 
Compensation was made for loss of time and inconvenience as a result of participation in the 
study. 
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ANAL YrICAL METHODS 
4.1 CHEMICAL OVERVIEW 










Androsterone, Department of Ph anna co logy, pure 
substance. 















Probenecid, Department of Pharmacology, pure 
substance. 











17a-methyltestosterone, Department of Pharmacology, 
pure substance. 
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Mefenamic Acid, Department of Pharmacology, 
pure substance. 
4.2.1 CHEMICALS AND REAGENTS 
Water was purified by RO 20SA (Millipore) reverse osmosis and Milli-Q® (Millipore) 
polishing system (Waters Assoc., Milford, MA, U.S.A.). All listed chemicals are of Pro 
Analyse quality or better, unless stated otherwise (Table 4.1). 
T£C::O' ~ i~ 
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Table 4.1 List of chemicals and reagents used. 
REAGENT/CHEMICAL SUPPLIER REF. No. 
Acetone Merck 000014.25 
Ammonium iodide Merck 1173 
Diethylether Merck UN 1863040 
1,4-Dithioerythritol Merck 24511 
Ethyl acetate Merck 9623 
~-glucuronidase [E. Coli] Boehringer 127680 
Methanol Merck 6009 
N-methyl-N-trimethylsilyl-trifluroacetamide Sigma M7891 
Potasium carbonate Merck 4928 
Potasium dihydrogen phosphate Merck 4873 
Sodium hydrogen carbonate Merck Art. 6329 
Sodium hydrogen phosphate Merck 6586 
Toluene Merck 8325 
4.2.2 BUFFERS 
4.2.2.1 PHOSPHATE BUFFER pH 7 
• Dissolve 14.196g sodium hydrogen phosphate in distilled water and dilute to I liter (I). 
• Dissolve 13.609g potasium dihydrogen phosphate in distilled water and dilute to I liter (2). 
• To I liter of (I) add sufficient of(2) to bring the pH to 7. Store at 4°C and boil before use. 
4.2.2.2 POTASIUM CARBONATE BUFFER pH 9.6 
• Dissolve 20g potassium carbonate and 20g sodium hydrogen carbonate in 160 ml distilled 
water. 
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4.3 ApPARATUS 
Standard laboratory glassware and equipment were used, with in addition: 
• Aluminium caps 
• Balances • Precisa (6200 D SCS) 
• Mettler (M3) 
• Mettler (PM 400) 
• Disiccator with vacuum facility 
• Disposable glass pipettes (Pasteur ISO 7712) 
• Electric heating block with adjustable thermostat (Thermolyne Type 17600) 
• Glass injector vials with glass inserts (Anatech) 
• Glass syringes (Hamilton) 
• Heating module thermostat adjustable with nitrogen facility (Techne Dri-Block® DB-3D) 
• Heraeus Labofuge 400 centrifuge (Function Line) 
• Horizontal shaker (Kotterman) 
• Sml Open amber ampoules (Anchor Rand) 
• pH-meter (Mettler Toledo) 
• Semi-automatic pipettes (Adjustable sample systems) 
• Sep-Pack C 18 cartridge (Waters, Millipore) 
• Vortex mixer (Thermo line Type 16700) 
4.4 EXTRACTION PROCEDURES 
4.4.1 ANDROSTERONE 
One (1) ml urine and one (1) ml distilled water were pipetted into a Sml ampoule. To the 
mixture, 1ml phosphate buffer pH 7 and 25J.!1 ~-glucuronidase enzyme (E.Coli) were added 
and hydrolysis was performed for 2 hours at 50°C. A Sep-Pak C 18 cartridge was activated by 
washing with 5ml methanol followed by 5ml distilled water. One (1) ml of the hydro Ii sed 
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urine solution was added to Sep-Pak CIS cartridge. The column was washed with 5ml of 
distilled water and the absorbed fraction was eluted with 3ml of methanol. As internal 
standard, 50fll 17a-methyltestosterone was added to the solution. The methanolic eluate was 
evaporated to dryness and the residue was dissolved in Iml of phosphate buffer pH 7. The 
buffered solution was alkalified with 200fll potasium carbonate solution to pH 9 - 10 and the 
androsterone was extracted with 4ml of diethyl ether by vortexing for 30 seconds. After 
centrifuging for 5 minutes at 2000 rpm the organic layer was transferred to a 5ml ampoule 
and evaporated to dryness under a stream of high purity nitrogen. The ampoules were left in 
an evacuated desiccator for at least 60 minutes. 
Derivatization 
40fll of the derivatization solution [lOml N-methyl-N-(trimethylsilyl)-tritluoroacetamide + 
20mg ammonium iodide + 40mg 1,4-dithioerythritol (1000:2:4 v/m/m)] was added to the dry 
residue, the ampoule was sealed and 15 minutes reaction time was allowed at 60°C. 200fll 
toluene was added and I fll of the solution was injected onto the GCIMSD in splitless mode 
(time to purge O.S min) . 
4.4.2 PROBENECID 
A Sep-Pak CIS cartridge was activated by washing with Sm! methanol followed by Sml 
distilled water. A half (0.5ml) ml urine was added to Sep-Pak CIS cartridge. The column was 
washed with 5ml of distilled water and the absorbed fraction was eluted with 2ml of 
methanol. The methanolic eluate was evaporated to dryness and the residue was dissolved in 
Iml of phosphate buffer pH 7. To the buffer solution, 2Sfll ~-glucuronidase enzyme (E.Coli) 
was added and hydrolysis was performed for I hour at SO°C. As internal standard, 50fll 
mefenamic acid was added to the buffered solution and the probenecid was extracted with 
I.Sml ethylacetate and 2.5ml diethyl ether by vortexing for 30 seconds. After centrifuging for 
S minutes at 2000 rpm, the organic layer was transferred to a Sml ampoule and evaporated to 
dryness under a stream of high purity nitrogen. The ampoules were left in an evacuated 
desiccator for at least 60 minutes. The residue was dissolved in 200fll acetone, SOmg 
potassium carbonate and 25 fll iodomethane were added. The ampoule was sealed and 30 
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minutes reaction time was allowed at 60°C. The solvent was transferred to another ampoule 
and evaporated to dryness under a stream of high purity nitrogen. The residue was dissolved 
in 500111 toluene and lill was injected into a gas chromatograph. 
4.5 INSTRUMENTAL AND CHROMATOGRAPHIC CONDITIONS 
4.5.1 ANDROSTERONE: GAS CHROMATOGRAPH-MASS SELECTIVE DETECTOR 
A Hewlett-Packard 6890 gas chromatograph with 6890 mass selective detector (GCIMSD), 
fitted with a ultra-l crosslinked methyl silicone column: 16.5m x O.2mm i.d., O.llilm film 
thickness was used (Hewlett-Packard). 
• Injection was performed by a Hewlett-Packard Model 6890 auto sampler. 
• Injection port temperature 250°C 
• Injection mode Splitless 
• Oven program Initial temp 1 100°C 
Initial time 1 0.0 
Rate 1 30°C/min 
Int temp 2 180°C 
Int time 2 0.0 
Rate 2 4°C/min 
Int temp 3 250°C 
Int time 3 0.0 
Rate 3 30°C/min 
Final temp 300°C 
Final time 0.5min 
Oven max 325°C 
• Carrier gas Helium (20mllmin) 
• Capillary column head pressure 8.8 psi 
• Flow Constant flow 
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Recording and integration were done by means of a Hewlett-Packard Vectra Workstation and 
the results printed on a Hewlett Packard Laser Jet 4 Printer. All data were captured and 




11.04 - 11.21 min 
14.45 - 14.64 min 
4.5.2 PROBENECID: GAS CHROMATOGRAPH 
A Hewlett-Packard 5890 A gas chromatograph, fitted with a Chrompack, WCOT fused silica, 
CP SIL 19CB column: 15m x 0.32mrn i.d., 0.25)lm film thickness was used (Hewlett-
Packard). 
• Injection was performed by a Hewlett-Packard Model 6890 auto sampler. 
• Injection temperature 
• Injection mode 
• Oven program 
• Detector 
• Detector temperature 
220°C 
Split less 
Initial temp 1 












Recording and integration were done by means of a Hewlett-Packard Vectra Workstation and 
the results printed on a Hewlett Packard Deskjet 600 Printer. All data were captured and 
stored, both in electronic form and as paper print-outs. 
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5.1Z5 - 5.179 min 
4.533 - 4.544 min 
4.6.1 STABILITY ON STANDARD SOLUTIONS 
4.6.1.1 ANDROSTERONE 
Standard solutions were freshly made up in methanol and used immediately to spike 
phosphate buffer pH 7 for the preparation of calibration standards and quality controls. 
Phosphate buffer was used instead of urine because androsterone is an endogenous steroid 
and therefore present in all urine samples. l7a-methyltestosterone (internal standard) was 
also made up in methanol and stored at -ZO°C. 
4.6.1.2 PROBENECID 
Standard solutions were freshly made up in methanol and used immediately to spike urine for 
the preparation of calibration standards and quality controls. Mefenamic acid (internal 
standard) was also made up in methanol and stored at -ZO°C. 
4.6.2 ON-INSTRUMENT STABILITY 
4.6.2.1 ANDROSTERONE 
The on-instrument stability was obtained from the quality control validation for androsterone 
(Table 4.Z). 
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4.6.2.2 PROBENECID 
The on-instrument stability was also obtained from the quality control validation for 
probenecid (Table 4.3). The downward trend of about 35% in the peak areas over nearly 12 
hours was attributed to a change of sensitivity of the NPD detector. This change did not 
influence the ratio ofprobenecid:internal standard as can be seen in Table 4.3. 
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Table 4.2 Summary of on-instrument stability of androsterone. 
ON-INSTRUMENT STABILITY OF ANDROSTERONE 
QUALITY CONTROL B 
PEAK AREA OF ANALYTE PEAK AREA or INT. STD. PEAK AREA IU TIQ TIME OF INJ. 
106 3475 0.0305 18:01 
109 3459 0.0315 22:26 
127 3941 0.0322 2:51 
127 3896 0.0326 7:16 
122 3696 0.0330 11:39 
n 5 5 5 
Mean 11 8 3693 0.032 
SD 10 226 0.001 
CV(%) 8.49 6.13 3.09 
QUALITY CONTROL E 
PEAK AREA OF ANAL YTE PEAK AREA OF INT. STD. PEAK AREA RATIO TIME OF INJ. 
12406 3811 3.2553 19:21 
13039 3990 3.2679 23:46 
13648 4146 3.2918 4: 11 
14368 4483 3.2050 8:35 
131 82 3988 3.3054 12:58 
n 5 5 5 
Mean 13329 4084 3.265 
SD 731 253 0.039 
CV(%) 5.49 6.19 1.19 
QUALITY CONTROL G 
PEAK AREA OF ANAL YTE PEAK AREA OF INT. STD. PEAK AREA RATIO TIME OF INJ. 
51836 4236 12.2370 20:14 
54618 4300 12.70 19 00:39 
55281 4202 13.1559 05:04 
51040 4111 12.4155 09:28 
51563 4027 12.8043 13 :5 1 
n 5 5 5 
Mean 52868 4175 12.663 
SD 1936 107 0.356 
CV(%) 3.66 2.57 2.81 
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Table 4.3 Summary of on-instrument stability of probenecid. 
ON-INSTRUMENT STABILITY OF PROBENECID 
QUALITY CONTROL A 
PEAK AREA OF ANAL YTE PEAK AREA OF INT. STD. PEAK AREA RATIO TIME OF INJ. 
206230 1184476 0.1741 19:08 
147061 811530 0.1812 21:02 
147163 79112 1 0.1860 22:56 
134097 715516 0.1874 0:50 
132254 696470 0.1899 2:33 
n 5 5 5 
Mean 153361 839823 0.184 
SD 30372 198721 0.006 
CV(%) 19.80 23.66 3.40 
QUALITY CONTROL C 
PEAK AREA OF ANALYTE PEAK AREA OF INT. STD. PEAK AREA RATIO TlME OF INJ. 
625792 1069257 0.5853 18:45 
580647 1049926 0.5530 20:39 
472981 853869 0.5539 22:33 
396095 707820 0.5596 0:27 
365205 642756 0.5682 2:10 
n 5 5 5 
Mean 488144 864726 0.564 
SD 113270 193740 0.013 
CV(%) 23.20 22.40 2.37 
QUALITY CONTROL F 
PEAK AREA OF ANAL YTE PEAK AREA OF INT. STD. PEAK AREA RATIO TIME OF INJ. 
3995866 940803 4.2473 18:01 
3761157 919869 4.0888 20:05 
3847918 912626 4.2163 21 :59 
3187401 766345 4.1592 23:53 
2978492 687263 4.3338 01:36 
n 5 5 5 
Mean 3554167 845381 4.209 
SD 444452 112276 0.092 
CV(%) 12.51 13.28 2.19 
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4.7 PRE-STUDY VALIDATION 
For this study, the assay methods were validated on the 13th of November 1996 for 
androsterone and on the 21th of July 1997 for probenecid with limited validation batches 
described here after. 
4.7.1 PREPARATION OF CALIBRATION STANDARDS AND QUALITY CONTROLS 
4.7.1. 1 ANDROSTERONE 
Calibration standards were prepared in phosphate buffer by preparation of a stock solution in 
a suitable solvent and spiking a certain volume to phosphate buffer pH 7 which was serially 
diluted with phosphate buffer to obtain the desired concentrations. All volumetric operations 
were performed by weighing and the masses of the phosphate buffer were converted to 
volumes when calculating concentrations. Quality controls were prepared in phosphate buffer 
by a competent person by the same method used for the calibration standards. Calibration 
standards and quality controls were divided into aliquotes and stored under the same 
conditions as the trial samples, approximately -20°C. The same calibration standards and 
quality controls as prepared for the method validation were used during the analysis of the 
study samples. The preparation data are reproduced in Table 4.4, Table 4.5 and Table 4.6. 
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CALIBRATION STANDARDS STOCK SOLUTION 
Solvent 
Specific gravity 












6.765mg Androsterone was dissolved in Iml of methanol and diluted with 245.09ml of 
phosphate buffer. 
CALIBRATION STANDARDS 
Table 4.4 Concentrations of calibration standards prepared in phosphate buffer. 
STDCODE A (g) B (g) C (g) 
K 110.690 356.780 ~ 
J 117.510 248.000 
I 118.550 238.540 
H 126.840 246.830 
G 109.890 229.890 
F 110.910 230.920 
E 110.560 230.570 
D 115.560 235.560 
C 110.400 230.400 
B 110.960 230.940 
A = Mass of empty container. 
B = Mass of container and phosphate buffer. 
C = Total mass of container plus normal plus spiked phosphate buffer. 
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(I) QUALITY CONTROL STOCK SOLUTION FOR QC G TO QC E 
Solvent Phosphate buffer 
Specific gravity 
Concentration of QC G 
1 kg/l 
25. 156flg/ml 
ANALYTE (mg) SOLVENT (g) SOLVENT (mt) CONe. (flg/ml) 
6.289 250.00 250.00 25.156 
6.289mg Androsterone was dissolved in Iml of methanol and diluted with 249.00ml of 
phosphate buffer. 
QUALITY CONTROLS 
Table 4.5 Concentration of quality controls, prepared in phosphate buffer. 
QCCODE A (g) B (g) C (g) 
G 118.080 368.080 t:}, ;,;;).> 
F 119.900 264.900 
E 109.070 254.080 
A = Mass of empty container. 
B = Mass of container and phosphate buffer. 
C = Total mass of container plus normal plus spiked phosphate buffer. 
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(II) QUALITY CONTROL STOCK SOLUTION FOR QC D TO QC A 
Solvent Methanol 
Specific gravity 0.791 kg/I 











Table 4.6 Concentration of quality controls, prepared in phosphate buffer. 
QC CODE A (g) B (g) C (g) 
D 103.080 363.090 It ·)f;));2)'~ 
C 111.150 131.060 
B 103.390 163.380 
A 104.610 144.620 
A = Mass of empty container. 
B = Mass of container and normal phosphate buffer. 
C = Total mass of container plus normal plus spiked phosphate buffer. 
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4.7.1.2 PROBENECID 
Calibration standards were prepared in urine by preparation of a stock solution in a suitable 
solvent and spiking a pool of normal urine which was serially diluted with normal urine to 
obtain the desired concentrations. All volumetric operations were performed by weighing and 
the masses of the biological fluid were converted to volumes when calculating 
concentrations. Quality controls were prepared in normal urine by a competent person by the 
same method used for the calibration standards. Calibration standards and quality controls 
were divided into aliquotes and stored under the same conditions as the trial samples, 
approximately -20°C. The same calibration standards and quality controls as prepared for the 
method validation were used during the analysis of the study samples. The preparation data 
are reproduced in Table 4.7, Table 4.8 and Table 4.9. 
CALIBRATION STANDARDS STOCK SOLUTION 
Solvent 
Specific gravity 












45 .818mg Probenecid was dissolved in Iml of methanol and diluted with 37.775ml of normal 
unne. 
43 
© Central University of Technology, Free State
CALIBRATION STANDARDS 
Table 4.7 Concentrations of calibration standards prepared in normal urine. 
STDCODE A (g) B (g) 
J 104.980 143.755 
I 110.550 123.000 
H 55.480 58.740 
G 39.740 54.320 
F 64.380 80.620 
E 109.060 127.650 
D 63.600 80.420 
C 108.440 126.440 
B 125.900 137.920 
A = Mass of empty container. 
B = Mass of container and normal biological fluid . 
C = Total mass of container plus normal plus spiked biological fluid. 










(I) QUALITY CONTROL STOCK SOLUTION FOR QC G TO QC E 
Solvent Normal urine 
Specific gravity 













ANALYTE (mg) SOLVENT (g) SOLVENT (m1) CONe. (J.!g/ml) 
50.048 47.221 47.221 1060 
50.048mg Probenecid was dissolved in Iml of methanol and diluted with 47.221ml of normal 
unne. 
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QUALITY CONTROLS 
Table 4.8 Concentration of quality controls, prepared in normal urine. 
QCCOOE A (g) B (g) 
G 81.150 128.371 I 
F 64.380 85.310 
E 64.920 80.620 
A = Mass of empty container. 
B = Mass of container and normal biological fluid. 
C = Total mass of container plus normal plus spiked biological fluid. 








(II) Q UALITY CONTROL STOCK SOLUTION FOR QC D TO QC A 
Solvent Methanol 
Specific gravity 0.791 kg/l 











Table 4.9 Concentration of quality controls, prepared in normal urine. 
QCCOOE A (g) B (g) 
D 109.990 179.990 
C 109.390 117.230 
B 103.380 118.630 
A 62.810 72.970 
A = Mass of empty container. 
B = Mass of container and normal biological fluid. 
C = Total mass of container plus normal plus spiked biological fluid. 
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4.7.2 CALIBRATION CURVE 
4.7.2.1 ANDROSTERONE 










0.056 - 27.490 J.!glml 
In(y) = a(ln xi + b(ln x) + c 
0.9996 
STO I - STO B 
20.14 - 758.26 J.!glml 
In(y) = a(ln X)2 + b(ln x) + c 
0.9998 
4.7.3 ACCURACY AND PRECISION OF THE QUALITY CONTROLS 
Accuracy is measured as % bias and precision is measured as coefficient of variation (CV%). 
4.7.3.1 ANDROSTERONE 
Table 4.10 Accuracy and precision as determined during the method validation. 
CODE ACTUAL DETERMINATION MEAN BIAS CV 
()!g/ml) 1 2 3 4 5 (%) (%) 
G 25.20 20.817 21.588 22.341 21.113 21.758 21.5232 -14.590 2.7 
F 12.60 11.573 11.690 11.467 11.284 11.328 11.4682 -8.983 1.5 
E 6.289 5.964 5.985 6.025 5.879 6.048 5.9800 -4.913 l.l 
D 0.260 0.289 0.234 0.238 0.249 0.278 0.2576 -0.923 9.6 
C 0.191 0.194 0.198 0.195 0.186 0.217 0.1979 3.613 5.8 
B 0.130 0.120 0.123 0.1 25 0.126 0.127 0.1242 -4.462 2.4 
A 0.061 0.073 0.050 0.057 0.085 0.075 0.068 11.475 21.2 
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4.7.3.2 PROBENECID 
Table 4.11 Accuracy and precision as determined during the method validation. 
CODE ACTUAL DETERMINA nON MEAN BIAS CV 
(J.1g1ml) 1 2 3 4 5 (%) (%) 
G 1060 904.19 989.68 1061.29 1116.79 1123.59 1039.107 -1.971 8.9 
F 589 641.37 613.93 635.99 626.10 656.45 634.766 7.770 2.5 
E 295 290.61 317.42 319.67 327.12 324.24 322.113 9.191 1.4 
D 94 91.40 100.38 99.70 99.3"5 100.31 99.937 6.316 0.5 
C 71.2 74.83 70.62 70.74 71.48 72.60 72.055 1.201 2.4 
B 47.50 44.39 47.20 47.93 46.55 47.24 46.662 -1.764 2.9 
A 24.00 22.44 23.32 23.92 24.09 24.40 23.635 -1.521 3.3 
4.7.4 CALIBRATION RANGE 
For the assignment of a valid calibration range, bias is taken as measure of accuracy, and 
coefficient of variation (CV%) is taken as measure of precision. Accuracy and precision for a 
valid range must be within 20% over the whole calibration range. Results from the validation 
assays above indicate a valid calibration range of 0.061 - 25.156 Ilglml for androsterone and 
24.0 - 1060.0 Ilglml for probenecid. For this study, the LLOQ (lower limit of quantification) 
was set to the lower limit of the calibration range, which was taken to be the calibration 
standard (0.056 Ilglml) for androsterone and calibration standard (19.7 Ilglml) for probenecid. 
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Figure 4.2 Representative chromatogram of androsterone for calibration standard G. 
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Figure 4.4 Representative chromatogram of androsterone for calibration standard B. 
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4.7.5.2 PROBENECID 
FlOI A, (003F0201.0) 
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Figure 4.5 Representative chromatogram of probenecid for calibration standard I. 
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Figure 4.6 Representative chromatogram of probenecid for calibration standard G. 
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Figure 4.7 Representative chromatogram of probenecid for calibration standard E. 
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5.1 STUDY EXECUTION 
samPles were assayed in batches. A batch consisted of calibration standards (usually 6 to 
~lO), quality controls (at high, medium and low concentrations), and study samples. 
Attempts were always made to process complete profiles of a subject for each treatment in a 
batch. Thus in a given batch, profiles of treatments were alternated whenever possible. The 
calibration standards and quality controls were interspersed among study samples in a 
predetermined manner, tabulated in a batch sample logistics table. The quality controls which 
were processed in each batch comprised duplicates near the maximum and near the mean 
concentration and three controls at respectively LLOQ, 2 x LLOQ and 3 x LLOQ (where 
LLOQ represents the lower limit of quantification determined during the validation of the 
assay method). After the batch had been run the chromatograms were inspected and checked 
against documented acceptance criteria. 
The calibration curves were plotted, regression equations determined, and the quality controls 
calculated as unknowns using the regression equation giving the best overall results 
throughout the study. 
5.1.1 PREPARATION OF CALIBRATION STANDARDS AND QUALITY CONTROLS 
The same calibration standards and quality controls as prepared for the pre-study validations 
were used during the analysis of the study samples. 
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5.1.2 TYPICAL BATCH STRUCTURE 
Samples were designated in the run sheet table by a three digit code seperated by commas 
consisting of subject number, sampling time (h) and period. The typical batch structure is 
detailed in Tables 5.1 and Table 5.2. 
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Table 5.1 Typical batch structure for androsterone. 
INJ. NO. SAMPLE INJ. NO. SAMPLE INJ . NO. SAMPLE 
I QCA 15 QCE 29 STDG 
2 QCB 16 15,3.0,1 30 15,24.0,1 
3 STDC 17 15,3.0,2 31 15,24.0,2 
4 STDC 18 STDE 32 QCF 
5 15,0.0,1 19 15,4.0,1 33 15,30.0, I 
6 15,0.0,2 20 15,4.0,2 34 15,30.0,2 
7 QCC 21 15,6.0,1 35 QCF 
8 15,1.0,1 22 15,6.0,2 36 15,36.0,1 
9 15,1.0,2 23 STDJ 37 15,36.0,2 
10 STDB 24 15,8.0,1 38 STD I 
11 STDB 25 15,8.0,2 39 15,48.0,1 
12 15,2.0,1 26 STDF 40 15,48.0,2 
13 15,2.0,2 27 15,12.0,1 41 QCD 
14 QCE 28 15,12.0,2 42 QCD 
Table 5.2 Typical batch structure for probenecid. 
INJ . NO. SAMPLE INJ. NO. SAMPLE INJ. NO. SAMPLE 
1 Response 16 QCD 31 QCC 
2 STDB 17 20,3.0,1 32 19,24.0,1 
3 19,0.0,1 18 QCD 33 20,24.0,1 
4 STDB 19 19,4.0,1 34 STDH 
5 20,0.0,1 20 20,4.0,1 35 19,30.0,1 
6 QCF 21 STDI 36 20,30.0,1 
7 19,1.0,1 22 19,6.0,1 37 QCB 
8 QCF 23 20,6.0,1 38 19,36.0,1 
9 20,1.0,1 24 STDD 39 20,36.0,1 
10 STDG 25 19,8.0,1 40 STDE 
11 19,2.0,1 26 20,8.0,1 41 19,48.0,1 
12 QCE 27 STDC 42 20,48.0,1 
13 20,2.0,1 28 19,12.0,1 43 QCA 
14 QCE 29 STDC 44 STDF 
15 19,3.0,1 30 20,12.0, I 
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Figure 5.4 Representative chromatogram for Subject I, period I, at 48 hours after start of 
profile. 
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5.1.3.2 PROBENECID 
FIOI A, (055F090I.D) 
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Figure 5.5 Representative chromatogram for Subject 17, period 2, before start of profile. 
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Figure 5.6 Representative chromatogram for Subject 17, period 2, 4 hours after start of 
profile. 
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Representative chromatogram for Subject 17, period 2, 12 hours after start of 
profile. 
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profile. 
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5.2 CALCULATION OF RESULTS 
Results were calculated using PhIRSt chromatographic data reporting package (Product of 
Phoenix International Life Sciences, Montreal, Canada). Peak areas were electronically and 
automatically read from the report files generated by Winner on Windows. Data were 
automatically summarised, calibration curves calculated according to pre-set regression 
equations and concentrations interpolated by the program. Results were presented in printed 
ordered tables with perfonnance statistics per batch and later summarized to give overall 
study statistics. This package has been validated in Canada by the manufacturer to Federal 
Drug Administration (FDA) requirements Phoenix International Life Sciences. 
TECHNI 
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RESULTS AND D ISCUSSION 
6.1 BIOMETRIC ANALYSIS 
6.1.1 SAMPLE SIZE 
The results of a pilot study (FRM 9/94) indicated that n = 20 subjects will be sufficient to 
obtain results with satisfactory precision. 
6.1.2 PHARMACOKINETIC AND SAFETY VARIABLES 
The fractional and cumulative unne volumes (-12-48h) and unnary probenecid and 
androsterone excretion (-12-48h), as well as the actual sampling times, were tabulated for 
each subject, product and collection interval, together with the following descriptive statistics 
for each product and collection interval: 
• The mean (MEAN). 
• The standard deviation (SD). 
• The geometric mean (GEOM MEAN). 
• The geometric standard deviation (GEOM SD). 
• The coefficient of variation (CV). 
• The standard error of the mean (SEM). 
• The minimum (MIN). 
• The maximum (MAX). 
• The median value (MEDIAN). 
• The number of observations (n). 
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6.1.3 ANALYSIS OF SAFETY DATA 
All haematological and clinical chemistry results from pre- and post-study examinations were 
summarized by descriptive statistics. The number of subjects with laboratory values outside 
the normal range, as well as individual data for all variables, were reported, but are not 
included in this dissertation. 
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6.2 RESUL TS AND DISCUSSION 
Individual results are reported in Appendix 6.1 and 6.2. Mean results are tabulated in this 
section. 
6.2.1 DEMOGRAPmC DATA 
Table 6.1 Demographic data of subjects participating in F ARMOVS 9196. 
SUBJECT No. AGE (YEAR) BODY MASS (kg) HEIGHT (em) 
I 30 72 191 
2 28 87 187 
3 25 76 176 
4 19 75 179 
5 24 80 182 
6 36 84 189 
7 34 68 179 
8 45 65 179 
9 30 70 176 
10* 27 92 184 
II 24 69 176 
12 25 77 184 
13 27 72 182 
14 24 69 176 
15 27 78 178 
16 23 66 188 
17 20 74 174 
18 23 79 175 
19 25 74 183 
20 22 73 175 
MEAN 27 75 180.7 
SD 5.99 6.96 5.19 
MIN 19 65 174 
MAX 45 92 191 
MEDIAN 25 74 179 
n 20 20 20 
'Subject 10 failed to complete the study due to flu. 
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Epitestos 12.63 2269 19 10 - 89 1 - 42 
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Figure 6.1 Printout of a normal steroid profile obtained form the screening method for 
anabolic steroids. 
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Figure 6.2 Printout of a steroid profile after the application of probenecid (Benemid®), 
obtained form the screening method for anabolic steroids. 
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Figure 6.2 (conI.) 
NORMAL RANGE 
RT AREA ng/ml Male Female 
ll.16 llO18 144 942 ' - 6027 404 - 5439 
ll.31 19189 319 652 - 4385 473 - 6107 
12.63 812 5 10 - 89 1 - 42 
13.32 304 2 5 - 90 1 - 57 
12.89 117 2 8 - 82 7 - 52 
ll.46 357 5 19 - 136 5 - 91 
ll.56 768 10 29 - 372 9 - 366 
12.95 90 **** *** - **** *** **** 
14.67 89668 
Printout of a steroid profile after the application of probenecid 
(Benemid®), obtained form the screening method for anabolic steroids. 
Figures 6.1 and 6.2 are representative examples of printouts obtained form the screemng 
method for anabolic steroids. Steroid profiling is a valuable tool when performed routinely on 
urinary doping control samples under carefully controlled analytical conditions. The 
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parameters of the unnary steroid profile are very stable but can be influenced by the 
application of probenecid, diuretics, ethanol etc. Also bacterial activities in the urine and side 
activities during the enzymatic hydrolysis may cause changes. All these factors lead to a 
characteristic pattern of the steroid profile. The ranges of the endogenous steroids that can be 
expected in a normal steroid profile, are also indicated in Figure 6.1. In Figure 6.2 probenecid 
can be seen at retention time 7.62 (ions: m/z = 328, m/z = 342). The presence of probenecid is 
further indicated by the suppression of the endogenous steroids in the steroid profile. Figure 


















76 I 270 M+ 
58 ioU, III. 121. 
135 152 
, I 298 314 357 89 I 211 226 243 
6'0' 
, 
80 100 120 140 160 180 200 220 240 260 280 300 320 340 
Electron impact ionization mass spectrum of a trimethylsilyl derivative of 
probenecid. 
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6.2.3 FRACTIONAL URINARY EXCRETION OF Al'IDROSTERONE 
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Figure 6.4 Geometric mean values (n = 19) of the urinary androsterone concentration 
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Figure 6.5 Geometric mean values (n = 19) of fractional urinary androsterone excretion 
over 48 hours. 
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The administration of probenecid leads to a significant decrease of the urinary concentration 
of androsterone (Figure 6.4). The lowest excretion (65.712f1g) was found between 2 - 3 hours 
after the administration of 4 x 500mg probenecid (Figure 6.5). The average excretion of 
androsterone in all the volunteers in the treatment phase (2 to 8 hours) was reduced to about 
6% of the average pretest levels. The decrease in the androsterone excretions in the placebo 
phase was due to the dilution of the urine by the intake of 200ml water hourly during the first 
four hours after treatment. This decrease was 33% of the average pretest levels (2 to 8 hours). 




ANDROSTERONE CONCENTRATION EXPRESSED PER M.MOL CREATININE 
- . - Treatment 
- - .. - - Placebo 
6 12 18 24 30 36 42 48 
Time (h) 
Geometric mean values (n = 19) of androsterone expressed per mmol 
creatinine over 48 hours. 
In order to compensate for the dilution effect of the urine the creatinine concentration of each 
fraction was measured and the androsterone concentration was expressed per mmol 
creatinine. From Figure 6.6 it is clear that the excretion of androsterone in the placebo phase 
remained constant, in contrast with the reduced excretion of androsterone in the treatment 
phase. This clearly demonstrates that probenecid suppressed the excretion of androsterone. 
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Geometric mean values (n = 19) of androsterone excretion rates (l!gIh) over 48 
hours. 
The data on the urinary excretion rate of androsterone are presented in Figure 6.7. The data 
were subjected to analysis of covariance, with the (-12 - 0 h) excretion rate as covariate. A 
statistically significant decrease in the excretion rate was seen from 2 to 8 hours after 
administration of a single dose of probenecid (4 x 500mg). The data on the percentage 
decrease of the excretion rates of the treatment phase relative to the control phase are 
presented in Table 6.2. The mean androsterone excretion rate for all fractional collection 
intervals in this period (1 - 2 h, 2 - 3 h, 3 - 4 h, 4 - 6 h, 6 - 8 h) were between 56% and 70% 
lower following administration of Benemid® than placebo. 
These results were confirmed by the cumulative urinary excretion of androsterone (Figure 
6.8). The mean cumulative urinary androsterone excretion (0 - 48 h) was 8027.8mg following 
placebo, and 6192.3mg following Benemid®, i.e. the mean excretion (0 - 48 h) following 
Benemid® was 77% of that following placebo. An analysis of covariance (with the baseline 
androsterone excretion as covariate), showed that the true 0 - 48 h androsterone excretion 
following Benemid® administration lies between 16% and 29% below that following placebo, 
with 90% certainty (90% confidence interval for the mean ratio "benemidlplacebo": 71-84%). 
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Table 6.2 Average decrease in the excretion rate of androsterone after administration of 
probenecid. 
TIME INTERVAL (b) PERCENTAGE DECREASE RELATIVE TO CONTROL 
0- 1 24 





8 - 12 34 
12 - 24 23 
24 - 30 11 
30 - 36 11 
36 - 48 -11* 
* A negalive value mdlcates an mcrease relalive to control. 
FARMOVS 9/96 
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Figure 6.10 Geometric mean values (n = 19) of probenecid concentration expressed per 
mmol creatinine over 48 hours. 
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The data on the excretion of probenecid are presented in Figure 6.9 and Figure 6.10. In order 
to compensate for the dilution effect of the urine the creatinine concentration of each fraction 
was measured and the probenecid concentration was expressed per mrnol creatinine (Figure 
6.10). Although a decrease in the excretion of androsterone, as a result of the administration 
of probenecid, was observed, the excretion of probenecid itself increased over the same 
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Figure 6.11 Comparison between the geometric mean values of androsterone and 
probenecid concentrations expressed per mrnol creatinine over 48 hours. 
6.2.7 CONCLUDING REMARKS 
The results from this study showed that the lowest excretion of androsterone was found 
between 2 - 3 hours after administration of probenecid. A statistically significant decrease in 
the excretion rate of androsterone was seen from 2 to 8 hours after administration of a single 
dose of probenecid (4 x 500mg). The mean androsterone excretion rate for all fractional 
collection intervals in this period (I - 2 h, 2 - 3 h, 3 - 4 h, 4 - 6 h, 6 - 8 h) were between 56% 
and 70% lower following administration of Benemid® compared to placebo. These results are 
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in agreement with those of Gardner et al., (1951) who reported that Benemid over a single 
24-hour period (Ig each 6 hours) produced approximately 50% deminution in urinary 17-
keto steroids (androsterone is also a 17-ketosteroid). 
The results of this study are also in agreement with Cunningham et al., (1981) who suggested 
that the co-administration of probenecid with a number of acidic compounds, particularly 
antibiotics, generally causes an increase in peak plasma concentrations and half-life and 
decrease in distribution half-life and urinary excretion of these compounds. 
Studies by Vree et al., (1995) also demonstrated that the oral clearance of furosemide, the 
renal clearance and the calculated non-renal clearance of furosemide were decreased by 
probenecid to approximately 35% of their baseline value. 
High doses of probenecid inhibit the unnary excretion of androsterone glucuronide and 
therefore it will also inhibit the excretion of other anabolic steroids excreted as glucuronides 
in urine. Since the concentrations of exogenous anabolic steroids in urine are usually very 
low, probenecid can decrease their concentration to below the limit of detection. Thus, 
probenecid can be used as a masking agent for the excretion of anabolic steroid glucuronides. 
This inhibition of the renal excretion of anabolic steroids by probenecid represents a 
manipulation of the urine sample in doping control and therefore probenecid was banned by 
the Medical Commission of the International Olympic Committee. 
For doping analysis only single urine samples, collected after a sporting event or out of 
competition are available. Normally, no information detailing the exact volume and time 
interval during which the urine was collected is available. Therefore, the urine concentration 
(~g/ml) of doping agents is the only measureable parameter. The excretion of non-conjugated 
metabolites of anabolic steroids is not affected by probenecid administration. 
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ApPENDIX 1 
RANDOMISA nON SCHEDULE FOR F ARMOVS 9/96 
SUBJECT TREATMENT PHASE I TREATMENT PHASE II 
1 B A 
2 A B 
3 A B 
4 B A 
5 B A 
6 A B 
7 B A 
8 A B 
9 B A 
10 A B 
11 B A 
12 B A 
13 A B 
14 A B 
15 A B 
16 B A 
17 A B 
18 B A 
19 B A 
20 B A 
Treatment 
A : Placebo (Control) 
B: Benemid® 2000mg (Probenecid) 
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ApPENDIX 2 
BODY MASS INDEX (BMI) AS IMPLEMENTED BY F ARMOVS 
BODY WEIGHT* IN KILOGRAMS ACCORDING TO HEIGHT** AND BODY MASS INDEX 
AGE GROUP (yr) 
Height (em) 18-24yr 25-34yr 35-44yr 45-54yr 55-64yr 65+yr 
140.0 33.5 - 51.7 35.3 - 53.9 37.1 - 56.1 38.8 - 58.2 40.6 - 60.4 42.3 - 62.5 
141.0 34.0 - 52.5 35.8 - 54.7 37.6 - 56.9 39.4-59.1 41.2-61.3 42.9 - 63.5 
142.0 34.5 - 53.2 36.3 - 55.4 38.1 - 57.6 40.0 - 59.8 41.8 - 62.2 43.6 - 64.3 
143.0 34.9 - 54.0 36.8 - 56 .2 38.6 - 58.5 40.5 - 60.7 42.4 - 63.0 44.2 - 65.2 
144.0 35.5 - 54.8 37.4 - 57.0 39.2 - 59.3 41.0-61.6 42.9 - 63.9 44.8 - 66.1 
145.0 36.0 - 55 .6 37.9 - 57.9 39.8 - 60.2 41.7 - 62.5 43.6 - 64.8 45 .5 - 67.1 
146.0 36.5 - 56.3 38.3 - 58.6 40.3 - 60.9 42.2 - 63.4 44.1-65.7 46.1 - 68.0 
147.0 37.0 - 57.1 38.9 - 59.5 40.9 - 61.8 42.8 - 64.2 44.7 - 66.6 46.7- 69.0 
148.0 37.4 - 57.9 39.4 - 60.3 41.4-62.7 43.4 - 65.0 45.4 - 67.4 47.3 - 69.8 
149.0 38.0 - 58.6 40.0 - 61.2 42.0 - 63.6 44.0 - 66.0 46.0 - 68.4 48.0 - 70.8 
150.0 38.5 - 59.4 40.5 - 61.9 42.6 - 64.3 44.6 - 66.9 46.6 - 69.3 48.6 - 71.8 
151.0 39.0 - 60.2 41.0 - 62.8 43.1-65.2 45.2 - 67.8 47.3 - 70.3 49.2 - 72.8 
152.0 39.5 - 60.9 41.6 - 63.6 43.7-66.1 45.7 - 68.6 47.8 - 71.2 49.9 - 73.7 
153.0 40.1-61.8 42 .1 - 64.5 44.3 - 67.0 46.4 - 69.5 48.4 - 72.2 50.6 - 74.7 
154.0 40.6 - 62.6 42.7 - 65.2 44.8 - 67.9 47.0 - 70.4 49.1-73.0 51.2-75.7 
155.0 41.1 - 63.5 43.3 - 66.1 45.5 - 68.8 47.6 - 71.3 49.8 - 74.0 51.9 -76.7 
156.0 41.6 - 64.2 43.8 - 66.9 46.0 - 69.6 48.2 - 72.3 50.4 - 74.9 52.6 - 77.7 
157.0 42.1 - 65.1 44.4 - 67.8 46.6 - 70.5 48.8 - 73.3 51.0 - 75.9 53.3 - 78.7 
158.0 42.7 - 65.9 44.9 - 68.6 47.2 - 71.4 49.4 - 74.1 51.7 - 76.9 53.9 - 79.6 
159.0 43.2 - 66.8 45.5 - 69.5 47.8 - 72.4 50.0 - 75.1 52.4 - 77.9 54.6 - 80.6 
160.0 43 .7 - 67.5 46.1 - 70.4 48.4 - 73.3 50.7 - 76.0 53.0 - 78.9 55.3 - 81.6 
161.0 44.4 - 68.4 46.7-71.3 49.1 - 74.1 51.3-77.0 53.7 - 79.9 56.0 - 82.7 
162.0 44.9 - 69.3 47.3 - 72.2 49.6 - 75.0 51.9 - 78.0 54.4 - 80.8 56.7 - 83.7 
163.0 45.5 - 70.2 47.9 - 73.0 50.2 - 76.0 52.7 - 79.0 55.1 - 81.8 57.4 - 84.8 
164.0 46.0 - 71.1 48.4 - 73.9 50.9 - 76.9 53.3 - 79.9 55.7 - 82.8 58.1-85.8 
165.0 46.6 - 71.8 49.1 - 74.9 51.5 - 77.9 53.9 - 80.8 56.4 - 83.9 58.8 - 86.9 
166.0 47.2 - 72.7 49.6 - 75.8 52.1 - 78.8 54.5 - 81.8 57.1 - 84.9 59.5 - 87.9 
167.0 47.7 - 73.6 50.2 - 76.8 52.7 - 79.8 55.3 - 82.8 57.8 - 85.9 60.2 - 88.9 
168.0 48.2 - 74.5 50.8 - 77.7 53.4 - 80.7 55.9 - 83.8 58.4 - 86.9 60.9 - 90.0 
169.0 48.9 - 75.5 51.4 - 78.5 54.0 - 81.7 56.6 - 84.8 59.1 - 88.0 61.7 - 91.1 
170.0 49.4 - 76.3 52.0 - 79.5 54.6 - 82.6 57.2 - 85.8 59.9 - 89.0 62.5 - 92.2 
171.0 50.0 - 77.2 52.7 - 80.5 55.3 - 83.6 57.9 - 86.9 60.6 - 90.0 63.2 - 93.3 
172.0 50.6 - 78 .1 53.3-81.4 55.9 - 84.6 58.6 - 87.9 61.2 - 91.1 63.9 - 94.4 
173.0 51.2-79.0 53.9 - 82.3 56.6 - 85.6 59.2 - 88.9 61.9 - 92.2 64.6 - 95.5 
174.0 51.8 - 80.0 54.5 - 83.3 57.2 - 86.6 59.9 - 89.9 62.6 - 93.3 65.4 - 96.6 
175.0 52.4 - 80.8 55.2 - 84.3 57.9 - 87.6 60.6 - 91.0 63.4 - 94.4 66.2 - 97.7 
176.0 53 .0 - 81.7 55.8 - 85.1 58.5 - 88 .6 61.3 - 92.0 64.1 - 95.4 66.9 - 98.8 
177.0 53.6 - 82.7 56.4 - 86.1 59.2 - 89.7 62.0-93.1 64.9 - 96.5 67.7-99.9 
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BODY MASS INDEX (BMI) AS IMPLEMENTED BY F ARMOVS (continued) 
BODY WEIGHT* IN KILOGRAMS ACCORDING TO HEIGHT** AND BODY MASS INDEX 
• 
•• 
Height (em) 18-24yr 2S-34yr 
178.0 54.2 - 83.6 57.1-87.1 
179.0 54.8 - 84.6 57.7-88.1 
180.0 55.4 - 85.6 58.3 - 89.1 
181.0 56.1 - 86.6 59.0 - 90.1 
182.0 56.6 - 87.5 59.6 - 91.1 
183.0 57.2 - 88.4 60.3 - 92.1 
184.0 57.9 - 89.4 60.9 - 93.1 
185.0 58.5 - 90.4 61.7 - 94.2 
186.0 59.1 - 91.3 62.3 - 95.2 
187.0 59.9 - 92.3 63.0 - 96.3 
188.0 60.5 - 93.3 63.6 - 97.2 
189.0 61.1 - 94.3 64.3 - 98.2 
190.0 61.7 - 95.3 65.0 - 99.3 
191.0 62.4 - 96.4 65.7 - 100.4 
192.0 63.0 - 97.3 66.3 - 101.4 
193.0 63.7 - 98.3 67.1 - 102.5 
194.0 64.3 - 99.3 67.8 - 103.5 
195.0 65.1 - 100.4 68.5 - 104.6 
196.0 65.7 - 101.4 69.1 - 105.6 
197.0 66.4 - 102.5 69.8 - 106.7 
198.0 67.1 - 103.5 70.6 - 107.8 
199.0 67.8 - 104.6 71.3 - 108.9 
200.0 68.4 - 105.6 72.0 - 110.0 
Weight: wearing indoor clothing 
Height: without shoes 
AGE GROUP (yr) 
3S-44yr 4S-S4yr SS-64yr 6S+yr 
59.9 - 90.6 62.7-94.1 65.6 - 97.6 68.4 - 101.1 
60.6 - 91.6 63.5 - 95.2 66.3 - 98.7 69.2 - 102.3 
61.2 - 92.6 64.2 - 96.3 67.1 - 99.8 70.0 - 103.4 
61.9 - 93.7 64.9 - 97.3 67.8 - 100.9 70.8 - 104.6 
62.6 - 94.7 65.6 - 98.3 68.6 - 102.0 71.6-105.7 
63.3 - 95.8 66.3 - 99.4 69.4 - 103.2 72.4 - 106.9 
64.0 - 96.8 67.1 - 100.5 70.1 - 104.3 73.2 - 108.0 
64.7 - 97.9 67.8 - 101.6 70.9 - 105.4 74.0 - 109.2 
65.4 - 98.9 68.5 - 102.7 71.6 - 106.6 74.7-110.3 
66.2 - 100.0 69.2 - 103.8 72.4 - 107.8 75.5 - 111.5 
66.8 - 101.1 70.0 - 104.9 73.2 - 108.9 76.3 - 112.8 
67.5 - 102.2 70.7 - 106.2 74.0 - 110.1 77.1- 114.0 
68 .2 - 103.3 71.5 - 107.3 74.7 - 111.2 77.9-115.2 
68.9 - 104.3 72.3 - 108.4 75.5 - 112.4 78.8-116.4 
69.7 - 105.4 73.0 - 109.5 76.3 - 113.5 79.7-117.6 
70.4 - 106.5 73.7 - 110.7 77.2 - 114.7 80.5 - 118.8 
71.1 - 107.7 74.5 - 111.8 78.1 - 115.9 81.3 - 120.0 
71.8 - 108.8 75.3 - 113.0 78.8 - 117.2 82.2 - 121.3 
72.6 - 109.9 76.1 - 114.1 79.6 - 118.4 83.0 - 122.5 
73.3 - 111.0 76.8 - 115.3 80.4 - 119.6 83.9 - 123.9 
74.1 - 112.1 77.6 - 116.5 81.2 - 120.8 84.7 - 125.1 
74.9 - 113.3 78.4-117.7 82.0 - 122.0 85.6 - 126.4 
75.6 - 114.4 79 .2 - 118.8 82.8 - 123.2 86.4 - 127.6 
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CERTIFICATE OF INSURANCE 
Price Forbes (Pty) Ltd 
Intemational Insurance Brokers and 
Risk Managers 
Reg No: 85/02410107 
ApPENDIX 3 
Forbes Financial Services Group (Pty) Ltd 
Price Forbes House 25 Sauer Street Ext 
Johannesburg 2001 
POBox 61689 Marshalltown 2107 
Tel. (011) 378 3000 Fax. (011) 378 3003 
Telex. 4-84392 SA 
Reg No: 69118487107 
CERTIFICATE OF INSURANCE 
Contract Number 622 Certificate Number CAlA02J6221481 
Lloyd's of London 
This Insurance is effected 'With certain Underwriters at Lloyd's London. 
This CertifICate is issued in accordance with the authOl'isation granted to Forbes Financial Services Group (Pty) Ltd, by certain 
Underwriters at Lloyd's, London whose syndicate numbers and the proportions underwritten by them can be ascertained 
from the office of Forbes Financial Services Group (Pty) ltd and in consideration of the premium specified herein, the 
Underwriters do hereby bind themselves severalty and not jointly, each for his OWT\ part and not fO( one another, their 
executors and administrators to insure in aooordance with the terms and condit ions described in this Certificate, 
Certificate Provisions 
1. All premiums are payable to Forbes Financial Services Group (Pty) Ltd at the address stated above in the currency 
of the Republic of South Africa. 
2. All claims are payable by the Underwriters, care of Forbes Financial Services Group (Pty) Ltd at the address stated 
above. 
3. This insurance shall be governed by the law of the Republic of South Africa. whose courts shall have jurisdiction in 
any dispute arising hereunder, and any summons, notice or process to be served upon the Underwriters for the 
purpose of instituting any legal proceedings against them in connection with this insurance may be served upon Mr 
R S Napier, cia Messrs Webber, Wentzel, Bowens, 2 .... Floor, 60 Main Stre:et. Johannesburg. 
4. It is expressly understood and agreed by the Insured by accepting this CertifICate that Forbes Financial Services 
Group (Pty) Ltd is not one of the Underwriters hereunder and neither is nor shall be in any way or to any extent 
liable for any loss or claim whatsoever, but the Underwriters hereunder are only those Underwriters whose names 
can be ascertained in the above mentioned Contract. 
5. This insurance is made and accepted subject to aU the provisions, conditions and It't"arranties set forth herein or in 
any forms or endorsements attached hereto, all of which are to be considered as incorporated herein and any 
provisions or conditions appearing in any forms or endorsements attached hereto wh ich alter the Certificate 
provisions stated above shall supercede such Certificata provisions insofar as they are inconsistent therewith. 
6. This Certificate shall not be assigned either in whole or in part without the written consent of Forbes Financial 
Services Group (pty) Ltd endorsed hereon. 
7. If you have any complaints concerning your insurance, please contact Forbes Financial Services Group (pty) Ltd 
8. This certificate shall not be valid unless Signed by Forbes Financial Servic~s Group (Pty) Ltd. 
Enclosures: Personal Accident/Illness Policy of Insurance. 
D~.:;z~otJU,ne 1996 
PRICE FORBES (PTY) LTD 
MANAGERS FOR FORBES FINANCIAL SERVICES GROUP (PTY) LTD 
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ApPENDLX4 
DECLARATION OF HELSINKI 
Recommendations guiding medical physicians in biomedical research involving human subjects. 
Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964. Amended by the 29th World 
Medical Assembly, Tokyo, Japan, October 1975, the 35th World Medical Assembly, Venice, Italy, October 
1983 and the 41st World Medical Assembly, Hong Kong, September 1989. 
INTRODUCTION 
It is the mission of the physician to safeguard the health of the people. His or her knowledge and conscience are 
dedicated to the fulfilment of this mission. 
The Declaration of Geneva of the World Medical Association binds the physician with the words "the health of 
my patient will be my first consideration" and the International Code of Medical Ethics declares that: "A 
physician shall act only in the patient's interest when providing medical care which might have the effect of 
weakening the physical and mental condition of the patient". 
The purpose of biomedical research involving human subjects must be to improve diagnostic, therapeutic and 
prophylactic procedures and the understanding of the aetiology and pathogenesis of disease. 
In current medical practice most diagnostic, therapeutic or prophylactic procedures involve hazards. This 
applies especially to biomedical research. 
Medical progress is based on research which ultimately must rest in part on experimentation involving human 
subjects. 
In the field of biomedical research, a fundamental distinction must be recognised between medical research in 
which the aim is essentially diagnostic or therapeutic for a patient, and medical research the essential object of 
which is purely scientific and without implying direct diagnostic or therapeutic value to the person subjected to 
the research. 
Special caution must be exercised in the conduct of research which may affect the environment and the welfare 
of animals used for research must be respected. 
Because it is essential that the results of laboratory experiments be applied to human beings to further scientific 
knowledge and to help suffering humanity. The World Medical Association has prepared the following 
recommendations as a guide to every physician in biomedical research involving human subjects. They should 
be kept under review in the future. It must be stressed that the standards as drafted are only a guide to 
physicians all over the world. Physicians are not relieved from criminal, civil and ethical responsibilities under 
the laws of their own countries. 
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1. BASIC PRINCIPLES 
1.1 Biomedical research involving human subjects must conform to generally accepted scientific principles 
and should be based on adequately performed laboratory and aninnal experimentation and on a 
thorough knowledge of the scientific literature. 
1.2 The design and performance of each experimental procedure involving human subjects should be 
clearly formulated in an experimental protocol which should be transmitted for consideration. 
comment and guidance to a specially appointed committee independent of the investigator and the 
sponsor provided that his independent committee is in conformity with the laws and regulations of the 
country in which the research experiment is perfonned. 
1.3 Biomedical research involving human subjects should be conducted only by scientifically qualified 
persons and under the supervision of a clinically competent medical person. The responsibility for the 
human subject must always rest with a medically qualified person and never rest on the subject of the 
research, even though the subject has given his or her consent. 
1.4 Biomedical research involving human subjects cannot legirimately be carried out unless the innportance 
of the objectives is in proportion to the inherent risk to the subject. 
1.5 Every biomedical research project involving human subjects should be preceded by careful assessment 
of predictable risks in comparison with foreseeable benefits to the subject or to others. Concern for the 
interests of the subject must always prevail over the interest of science and society. 
1.6 The right of the research subject to safeguard his or her integrity must always be respected. Every 
precaution should be taken to respect the privacy of the subject and to minimise the innpact of the study 
on the subject's physical and mental integrity and on the personality of the subject. 
I. 7 Physicians should abstain from engaging in research projects involving human subjects unless they are 
satisfied that the hazards involved are believed to be predictable. Physicians should cease any 
investigation if the hazards are found to outweigh the potential benefits. 
1.8 In publication of his or her results , the physician is obliged to preserve the accuracy of the results. 
Reports of experimentation not in accordance with the principles laid down in this Declaration, should 
not be accepted for publication. 
1.9 In any research on human beings, each potential subject must be adequately informed of the aims, 
methods, anticipated benefits and potential hazards of the study and the discomfort it may entail. He or 
she should be informed that he or she is at liberty to abstain from participation in the study and that he 
or she is free to withdraw his or her consent to participation at any time. The physician should then 
obtain the subject's freely-given infonned consent, preferable in writi~g. 
\.10 When obtaining informed consent for the research project, the physician should be parricularly 
cautious if the subject is in a dependent relationship to him or her or may consent under duress. In that 
case the informed consent should be obtained by a physician who is not engaged in the investigation 
.and who is completely independent of this official relationship. 
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1.11 In case of legal incompetence, informed consent should be obtained from the legal guardian in 
accordance with the legislation. Where physical or mental incapacity makes it impossible to obtain 
informed consent, or when the subject is a minor, permission from the responsible relative replaces that 
of the subject in accordance with national legislation. Whenever the minor child is in fact able to give a 
consent, the minor's consent must be obtained in addition to the consent afthe minor's legal guardian. 
1.12 The research protocol should always contain a statement of the ethical considerations involved and 
should indicate that the principles enunciated in the present Declaration are complied with. 
2. MEDICAL RESEARCH COMBINED WITH PROFFESIONAL CARE 
(Clinical Research) 
2.1 In the treatment of the sick person, the physician must be free to use a new diagnostic and therapeutic 
measure, if in his or her judgement it offers hope of saving life, re-establishing health or alleviating 
suffering. 
2.2 The potential benefits, hazards and discomfort of a new method should be weighed against the 
advantages of the best current diagnostic and therapeutic methods. 
2.3 In any medical study, every patient - including those of a control group, if any - should be assured of 
the best proven diagnostic and therapeutic method. 
2.4 The refusal of the patient to participate in a study must never interfere with the physician-patient 
relationship. 
2.5 If the physician considers it essential not to obtain informed consent, the specific reasons for this 
proposal should be stated in the experimental protocol for transmission to the independent committee 
(1.2). 
2.6 The physician can combine medical research with professional care, the objective being the acquisition 
of new medical knowledge, only to the extent that medical research is justified by its potential 
diagnostic Of therapeutic value for the patient. 
3 . NON-THERAPEUTIC BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS 
(Non-clinical Biomedical Research) 
3.1 In the purely scientific application of medical research carried out on a human being, it is the duty of 
the physician to remain the protector of the life and health of that person on whom biomedical research 
is being carried out. 
3.2 The subjects should be volunteers - either healthy persons or patients for whom the experimental 
design is not related to the patient's illness. 
3.3 The investigator or the investigating team should discontinue the research if in hislher or their 
judgement it may, if continued, be harmful to the individual. 
3.4 In research on man, the interest of science and society should never take precedence over 
considerations related to the well-being of the subject. 
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ApPENDIX 5 
QUALITY ASSUR<\NCE STATEMENT 
A STUDY TO DETERMINE THE INFLUENCE OF PROBENECID (BENEMID®) ON THE UR1NARY 
EXCRETION OF ANDROSTERONE 
This report has been audited by die Quality Assurance Division of the F ARMOVS Research 
Centre. It is considered to be an accurate presentation of the findings as well as a precise 
account of the procedures and practices employed during the performance of the study. 
The following audits were performed: 
{'{I01Ift Pre-study audit 
Post-study audit (clinical) 
------
06 I /J.I '76 
The following guidelines were in use: 
* In-house SOP's 
* Declaration of Helsinki 
* Good Clinical Practice for Trials on Medicinal Products in the European Community. 
In: The Rules Governing Medicinal Products in the European Community. Volume 
III. Addendum no 2. Guidelines on the quality, safety and efficacy of medicinal 
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RAw DATA - ANDROSTERONE 
F ARMOVS 9/96 
























GEOM MEAN 448.630 
GEOM SD 1.445 
CV % 37.736 
SEM 41.420 
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FARMOVS 9/96 
URINARY VOLUMES (mil 
BENEMID 























GEOM MEAN 466.726 
GEOM SD 1.655 
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FARMOVS 9/96 
CUMULATIVE URINARY VOLUMES (m1) 
PLACEBO 






















GEOM MEAN 105.495 
GEOM SD 1.836 

















































































































758 .210 914.310 
1110.660 1233.010 
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FARMOVS 9/96 
CUMULATIVE URINARY VOLUMES (011) 
BENE MID 
DOSE: 4 X 500 MG PROIIENECID TABLETS 
SUBJECT o to I h o to 2 h o to 3 h o to 4 h o to 6 h o to 8 h o to 12 h o to 24 h o to 30 h o to 36 h o to 48 h 
125.330 248.970 700.840 1385.790 2171.130 2313.130 2587 .290 3173.590 3433.270 3933.520 4358.110 
2 309.390 849.690 1249.810 1547.910 1876.260 2097.060 2377.720 2873.480 3072.760 3241.780 3731.230 
3 51.340 124.840 393.140 968.430 2156.140 3121.470 3480.340 3893.610 4067.340 4400.160 4995.260 
4 107.800 443.920 675.670 1041.410 1167.290 1339.290 1500.670 1795.070 2283.070 2714.070 3313.950 
5 140.770 275.320 688.510 993.830 1220.820 1442.820 1746.120 2265.120 2613.670 2834.640 3839. 170 
6 112.660 259.870 528.640 927.260 1272.460 1436.210 1787.350 2173.000 2414.540 2645.190 2946.830 
7 98.550 473.920 927.830 1428.730 1712.910 2086.500 2398.650 3101.300 3350.290 3625.980 4258.060 
8 162.680 312.520 384.910 447.420 548 .020 648.020 1975.610 2551.700 2763.360 2910.310 3222.090 
9 141.190 760.150 1459.460 2251.300 3720.110 4744.630 5412.480 6407.940 7185.520 7463.120 79 15.250 
II 127.450 880.170 1554.990 2245.710 2603.400 2689.400 2961.900 3347.340 3625.330 4023.430 4384.320 
12 258 .820 655.270 1096.320 1522.010 1857.600 2091.130 2383.730 3120.730 3258.350 3544.750 4051.250 
13 114.160 231.160 457.880 910.920 1546.920 1724.150 2119.400 3018.240 3246.490 3383.710 3965.010 
14 49.930 115.920 166.320 402.440 602.700 769.390 1034.000 1472.960 1660.130 1830.900 2072.840 
15 234.000 616.160 981.910 1241.700 1558.750 1713.650 2036.940 2618.870 3263.800 3553.480 4221.500 
16 156.590 434.140 922.440 1113.190 1486.450 2076.610 2451.760 2709.760 2966.620 3319.620 3974.680 
17 96.140 616.920 1160.920 1443.920 1938.130 2888.220 3360.140 3763.410 4013.480 4167.520 4533.760 
18 203.850 753.660 1098.920 1534.620 1969.400 2056.400 2436.780 2904.070 3654.680 3784.160 4537.530 
19 251.450 390.550 546.660 632.030 751.130 1101.660 1299.920 1764.390 1972.900 1972.900 2029.080 
20 80.080 184.180 562.900 1311.270 1547.070 1681.450 1846.990 2555.650 2646.190 2980.890 3474.600 
MEAN 148.536 454 .070 818.846 1228.942 1668.773 2001.115 2378.831 2921.591 3236.410 3491.059 3990 .764 
SO 72.104 246.842 384.456 499.545 735.371 932.763 968.832 1060.453 1154.555 1182.348 1234.811 
GEOMMEAN 132.484 384.631 721.730 1123.414 1511.938 1810.065 2222.995 2771.729 3082.109 3335.143 3825.007 
GEOMSO 1.654 1.869 1.743 1.584 1.612 1.602 1.451 1.385 1.365 1.328 1.351 
CV% 48.543 54.362 46.951 40.648 44.067 46.612 40.727 36.297 35.674 33.868 30.942 
SEM 16.542 56.629 88.200 114.604 168.706 213.991 222.265 243.284 264.873 271.249 283.285 
MIN 49.930 115.920 166.320 402.440 548.020 648.020 1034.000 1472.960 1660.130 1830.900 2029.080 
MAX 309.390 880.170 1554.990 2251.300 3720.110 4744.630 5412.480 6407.940 7185 .520 7463.120 7915.250 
MEDIAN 127.450 434.140 700.840 1241.700 1558.750 2056.400 2377.720 2873.480 3246.490 3383.710 3974.680 
N 19 19 19 19 19 19 19 19 19 19 19 
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FARMOVS 9/96 
URINARY ANDROSTERONE CONCENTRATION ("g/ml) 
LLOQ ~ O.06"glml 
PLACEBO 






















GEOM MEAN 3.578 
GEOM SD I. 722 
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FARMOVS 9/96 
URINARY ANDROSTERONE CONCENTRATION ("g/ml) 
LLOQ = 0.06"g/ml 
BENEMID 
DOSE: 4 X 500 MG PROBENECID TABLETS 






















GEOM MEAN 4.027 
GEOM SO 1.701 

























































































































































































































12 to 24 h 24 to 30 h 30 to 36 h 
1.329 1.676 2.559 
1.823 2.417 3.447 
4.209 6.430 4.824 
3.433 4.666 7.998 
3.366 4.102 6.359 
4.249 5.196 6.620 
1.642 3.146 3.437 
1.137 2.220 2.919 
2.038 0.945 2.708 
2.675 3.009 1.838 
1.384 8.258 4.748 
1.146 2.759 2.693 
2.463 2.919 3.341 
3.245 4.400 1.810 
9.562 7.119 5.145 
2.292 4.334 1.336 
0.671 1.726 2.231 
3.707 8.199 Missing 
1.305 2.112 2.067 
2.720 3.981 3.671 
1.988 2.200 1.881 
2.242 3.418 3.262 
1.866 1.796 1.646 
73.090 55.263 51.229 
0.456 0.505 0.443 
0.671 0.945 1.336 
9.562 8.258 7.998 
2.292 3.146 3.130 
19 19 18 
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FARMOVS 9/96 
FRACTIONAL URINARY ANDROSTERONE EXCRETION (fig) 
PLACEBO 






















GEOM MEAN 1605.153 
GEOM SD 1.564 
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FARMOVS 9/96 
FRACTIONAL URINARY ANDROSTERONE EXCRETION (I'g) 
BENEMID 
DOSE: 4 X 500 MG I'ROBENECID TABLETS 
SUBJECT -12100h 010 I h I 102 h 2103 h 3104 h 4106 h 6108 h 81012 h 121024h 241030 h 301036 h 361048 h 
2120.558 373.859 75.544 73.203 89.728 153.141 77.958 272.241 779.193 435.224 1280.140 1606.224 
2 1500.763 342.185 65.917 36.811 43.523 56.476 147.936 320.514 903.770 481.660 582.612 2013.108 
3 1589.973 312.712 70.707 70.295 101.251 224.477 222.991 381.838 1739.453 1117.084 1605.524 2562.501 
4 2855.329 848.709 120.667 58.401 231.513 163.140 329.380 671.986 1010.675 2277.008 3447.138 3520.696 
5 2214.242 676.400 89.745 104.950 54.347 83.986 310.134 461.319 1746.954 1429.752 1405.148 2097.459 
6 1691.852 503.140 144.560 95.682 90.487 180.540 235.473 533.382 1638.627 1255.042 1526.903 2302.418 
7 1362.742 377.348 36.036 45.391 39.571 68.203 152.425 207.268 1153.751 783.323 947.547 1236.981 
8 1162.781 271.676 89.155 78.181 106.455 191.844 103.900 330.570 655.014 469.885 428.947 942.199 
9 1515.313 367.235 99.653 81.120 76.808 195.352 193.634 352.625 2028.747 734.813 751.741 1271.390 
II 1547.797 435.497 72.261 72.881 73.216 46.857 42.742 372.508 1031.052 836.472 731.708 2244.014 
12 2071.956 568.110 69.379 63.952 93.652 101.013 204.105 347.024 1020.008 1136.466 1359.827 577.917 
13 1797.110 313.712 30.654 58.947 68.409 186.348 124.770 323.710 1030.071 629.742 369.533 2260094 
14 1846.253 134.711 33.391 28.728 46.043 57.475 96.514 312.504 1081.158 546.349 570.543 1019.777 
15 3802.228 721.422 139.488 86.683 88.588 202.278 267.048 692.164 1888.363 2837.692 524.321 2218.494 
16 3394.177 574.842 49.126 96.195 93.849 178.418 154.622 581.483 2466.996 1828.586 1816.185 3412.863 
17 1515.249 380.426 487.450 Missing 35.658 50.904 253.674 451.156 924.295 1083.803 205.797 1665.293 
18 1022.965 316.783 48.383 40.050 40.084 58.261 85.521 314.574 313.552 1295.553 288.870 1284.496 
19 2659.269 2492.121 70.524 63.693 50.368 122.316 388.387 474.833 1721.790 1709.573 Missing 350.058 
20 2191.270 166.006 24.359 27.647 50.141 35.370 122.958 159.249 924.801 191.220 691.825 1652.447 
MEAN 1992.728 535.626 95.632 65.712 77.563 124.021 184.956 397.944 1266.225 1109.434 1029.684 1802.022 
SD 736.822 508.202 100.955 23.210 44.063 64.998 94.452 143.650 546.644 681.359 779.573 849.633 
GEOMMEAN 1879.623 426.751 72.976 61.278 69.309 105.728 161.020 373.617 1147.614 919.166 809.404 1578.533 
GEOMSD 1.412 1.874 1.975 1.498 1.591 1.841 1.765 1.450 1.617 1.937 2.057 1.782 
CV% 36.976 94.880 105.567 35.321 56.809 52.409 51.067 36.098 43.171 61.415 75.710 47.149 
SEM 169038 116.589 23.161 5.471 10.109 14.912 21.669 32.956 125.409 156.315 183.747 194.919 
MIN 1022.965 134.711 24.359 27.647 35.658 35.370 42.742 159.249 313.552 191.220 205.797 350.058 
MAX 3802.228 2492.121 487.450 104.950 231.513 224.477 388.387 692.164 2466.996 2837.692 3447.138 3520.696 
MEDIAN 1797.110 377.348 70.707 67.123 73.216 122.316 154.622 352.625 1031.052 1083.803 741.724 1665.293 
N 19 19 19 18 19 19 19 19 19 19 18 19 
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FARMOYS 9/96 
CUMULATIYE URINARY ANDROSTERONE EXCRETION (fig) 
PLACEBO 
SUBJECT -12 to 0 h o to I h o to 2 h o to 3 h o to 4 h o to 6 h o to 8 h o to 12 h o to 24 h o to 30 h o to 36 h o to 48 h 
1220.778 468.676 628.349 755.206 895.811 1213.190 1567.304 2092.300 3579.192 4570.247 5703.083 7081. 106 
2 1455.253 464.987 675.651 944.086 1194.449 1331.058 1821.853 2376.119 3674.968 4136.446 5440.321 7299.018 
3 2728.895 529.468 805.287 1103.420 1485.063 1852.130 2308.286 3292.826 4951.928 5930.109 7325.766 9327.600 
4 2849.610 723.162 1140.667 1487.453 1845.989 2039.283 3001.344 4038.720 4713.094 9131.042 10549.298 14177.354 
5 1448.228 898.023 1268.268 1491.460 1735.328 2110.588 2663.874 3176.334 5483.665 6807.887 7455.296 9293.296 
6 2018.927 550.088 812.940 1052.728 1227.817 1679.032 2289.979 3148.661 4713.432 6306.881 7729.523 9443.941 
7 1654.408 509.434 730.006 869.233 1011.413 1253.343 1440.621 1808.220 3302.929 4251.566 4928.935 6348.655 
8 1216.235 325.015 505.119 686.883 844.536 1003.330 1334.340 I7I1.l27 2754.973 3495.867 4266.705 5111.979 
9 1004.927 389.029 589.729 796.445 960.843 1067.428 1671.964 2141.855 3368.243 4081.410 5190.468 6925.078 
II 2403.768 428.217 852.325 984.613 1177.683 1512.993 2216.483 2552.419 4385.437 5673.969 7033.637 9688.672 
12 633.855 288.237 728.816 1236.375 1664.257 2029.323 2450.142 3284.492 4794.824 6435.473 7272.563 7798.021 
13 1862.455 495.420 656.875 797.440 965.238 1218.855 1595.649 2346.004 3771.438 4878.441 5648.979 7212.972 
14 1860.453 338.472 514.432 673.382 872.574 \153.710 1612.967 1885.474 4158.008 5466.372 7205.405 9337.789 
15 2455.272 1014.808 1368.340 1703.888 2023 .310 2282.497 3378.285 5126.511 7378.571 10255.407 11947.755 15395.621 
16 3538.488 487.445 889.470 1331.022 1743.806 1954.421 2677.977 4075.872 7289.198 9067 .301 11057.977 11846.590 
17 1617.842 826.249 1061.708 1291.881 1524.773 1787.549 2305.395 3313.570 4589.889 4971.426 5136.542 6913.890 
18 828.222 593.4 10 881.500 1374.553 1594.781 1749.113 2 \11.890 2396.801 3195.211 3347.311 3598.851 4176.213 
19 992.339 449.189 785.983 1169.570 1636.142 2176.392 2902.294 3310.336 5782.089 6864.073 6864.073 8015.533 
20 1612.381 303.892 554.052 669.952 792.977 893.383 1313.182 1435.261 2538.919 3407.499 3672.026 5056.090 
MEAN 1758.018 530.696 813.133 1074.715 1326.147 1595.138 2140.202 2816.469 4443.474 5740.986 6738.274 8444.706 
SD 760.115 202.269 246.071 314.308 391.889 442.311 607.609 950.046 1343.779 2010.031 2360.736 2913.016 
GEOM MEAN 1605.153 498.758 780.892 1031.488 1270.313 1534.079 2058.899 2671.265 4264.664 5437.749 6375.879 8006.682 
GEOM SD 1.564 1.427 1.334 1.344 1.356 1.340 1.333 1.398 1.340 1.397 1.418 1.397 
CV% 43.237 38.114 30.262 29.246 29.551 27.729 28.390 33.732 30.242 35.012 35.035 34.495 
SEM 174.382 46.404 56.453 72.107 89.905 101.473 139.395 217.955 308.284 461.133 541.590 668.292 
MIN 633.855 288.237 505.119 669.952 792.977 893.383 1313.182 1435.261 2538.919 3347.311 3598.851 4176.213 
MAX 3538.488 1014.808 1368.340 1703.888 2023.310 2282.497 3378.285 5126.511 7378.571 10255.407 11947.755 15395.621 
MEDIAN 1617.842 487.445 785.983 1052.728 1227.817 1679.032 2216.483 2552.419 4385.437 5466.372 6864.073 7798.021 
N 19 19 19 19 19 19 19 19 19 19 19 19 
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FARMOVS 9/96 
CUMULATIVE URINARY ANDROSTERONE EXCRETION (I'g) 
BENE MID 
DOSE: 4 X 500 MG PROBENECfJ) TABLETS 
SUBJECT -12toOh o to I h o to 2 h o to 3 h o to 4 h o to 6 h o to 8 h o to 12 h o to 24 h o to 30 h 01036 h o to 48 h 
2120.558 373.859 449.403 522.606 612.335 765.476 843.434 1115.675 1894.868 2330.091 3610.231 5216.455 
2 1500.763 342.185 408.102 444.913 488.436 544.912 692.848 1013.362 1917.132 2398.792 2981.404 4994.512 
3 1589.973 312.712 383.419 453.714 554.965 779.442 1002.433 1384.271 3123.724 4240.808 5846.332 8408.832 
4 2855.329 848.709 969.376 1027.777 1259.291 1422.431 1751.811 2423.798 3434.473 5711.481 9158.619 12679.315 
5 2214.242 676.400 766.145 871.095 925.442 1009.428 1319.562 1780.882 3527.836 4957.588 6362.736 8460.194 
6 1691.852 503.140 647.700 743.382 833.869 1014.408 1249.881 1783.262 3421.889 4676.931 6203.834 8506.252 
7 1362.742 377.348 413.383 458.774 498.346 566.549 718.973 926.241 2079.992 2863.315 3810.861 5047.842 
8 1162.781 271.676 360.830 439.oJ2 545.466 737.310 841.210 1171.780 1826.795 2296.680 2725.627 3667.826 
9 1515.313 367.235 466.888 548.008 624.816 820.168 1013.802 1366.427 3395.174 4129.988 4881.728 6153.118 
11 1547.797 435.497 507.758 580.638 653.855 700.712 743.454 1115.962 2147.014 2983.485 3715.193 5959.207 
12 2071.956 568.110 637.489 701.441 795.093 896.105 1100.211 1447.234 2467.242 3603.708 4963.535 5541.452 
13 1797.110 313.712 344.366 403.313 471.722 658.070 782.840 1106.550 2136.620 2766.362 3135.895 5395.990 
14 1846.253 134.711 168.102 196.830 242.873 300.348 396.862 709.366 1790.525 2336.874 2907.416 3927.193 
15 3802.228 721.422 860.910 947.593 1036.182 1238.459 1505.507 2197.671 4086.034 6923.726 7448.047 9666.541 
16 3394.177 574.842 623.968 720.163 814.012 992.431 1147.053 1728.535 4195.531 6024.117 7840.302 11253.165 
17 1515.249 380.426 867.876 867.876 903.534 954.438 1208.112 1659.267 2583.562 3667.365 3873.163 5538.456 
18 1022.965 316.783 365.166 405.216 445 .301 503.561 589.082 903.657 1217.208 2512.761 2801.631 4086.127 
19 2659.269 2492.121 2562.645 2626.338 2676.706 2799.022 3187.409 3662.241 5384.032 7093.605 7093.605 7443.663 
20 2191.270 166.006 190.365 218.012 268.153 303.523 426.480 585.730 1510.531 1701.752 2393.576 4046.024 
MEAN 1992.728 535.626 631.257 693.511 771.073 895.094 1080.051 1477.995 2744.220 3853.654 4829.144 6631.167 
SO 736.822 508.202 518.601 522.798 528.503 542.803 620.084 715.594 1087.118 1646.823 2030.522 2569.752 
GEOM MEAN 1879.623 426.751 517.493 582.239 662.240 785.191 957.778 1344.403 2552.335 3543.507 4450.326 6212.796 
GEOM SD 1.412 1.874 1.838 1.780 1.716 1.670 1.629 U51 1.480 1.521 1.506 1.440 
CV% 36.976 94.880 82.154 75.384 68.541 60.642 57.412 48.417 39.615 42.734 42.047 38.753 
SEM 169.038 116.589 118.975 119.938 121.247 124.527 142.257 164.168 249.402 377.807 465.834 589.541 
MIN 1022.965 134.711 168.102 196.830 242.873 300.348 396.862 585.730 1217.208 1701.752 2393.576 3667.826 
MAX 3802.228 2492.121 2562.645 2626.338 2676.706 2799.022 3187.409 3662.241 5384.032 7093.605 9158.619 12679.315 
MEDIAN 1797.110 377.348 466.888 548.008 624.816 779.442 1002.433 1366.427 2467.242 3603.708 3873.163 5541.452 
N 19 19 19 19 19 19 19 19 19 19 19 19 
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FARMOVS 9/96 
ANDROSTERONE EXCRETION RATE (flg/hr) 
PLACEBO 
SUBJECT -12100 h 010 I h I 102 h 2103 h 3104 h 4106 h 6108 h 810 12 h 121024 h 241030 h 301036 h 361048 h 
I 101.731 468.676 159.673 126.857 140.606 158.690 177.057 131.249 123.908 165.176 188.806 114.835 
2 121.271 464.987 210.665 268.435 250.362 68.305 245.397 138.567 108.237 76.913 217.312 154.891 
3 227.408 529.468 275.819 298.133 381.643 183.534 228.078 246.135 138.258 163.030 232.610 166.819 
4 237.468 723.162 417.505 346.786 358.536 96.647 481.031 259.344 56.198 736.325 236.376 302.338 
5 120.686 898.023 370.245 223.192 243.868 187.630 276.643 128.115 192.278 220.704 107.901 153.167 
6 168.244 550.088 262.853 239.788 175.088 225.608 305.473 214.671 130.398 265.575 237.107 142.868 
7 137.867 509.434 220.572 139.227 142.180 120.965 93.639 91.900 124.559 158.106 112.895 118.310 
8 101.353 325.015 180.104 181.764 157.653 79.397 165.505 94.197 86.987 123.482 128.473 70.440 
9 83.744 389.029 200.701 206.715 164.398 53.293 302.268 117.473 102.199 118.861 184.843 144.551 
II 200.314 428.217 424.107 132.288 193.070 167.655 351.745 83.984 152.752 214.755 226.611 221.253 
12 52.821 288.237 440.579 507.559 427.883 182.533 210.410 208.588 125.861 273.442 139.515 43.788 
13 155.205 495.420 161.455 140.565 167.799 126.809 188.397 187.589 118.786 184.501 128.423 130.333 
14 155.038 338.472 175.961 158.950 199.192 140.568 229.629 68.127 189.378 218.061 289.839 177.699 
15 204.606 1014.808 353.533 335.548 319.422 129.593 547.894 437.057 187.672 479.473 282.058 287.322 
16 294.874 487.445 402.025 441.552 412.784 105.307 361.778 349.474 267.777 296.350 331.779 65.718 
17 134.820 826.249 235.459 230.173 232.892 131.388 258.923 252.044 106.360 63.590 27.519 148.112 
18 69.019 593.410 288.091 493.053 220.228 77.166 181.388 71.228 66.534 25.350 41.923 48.114 
19 82.695 449.189 336.794 383.588 466.571 270.125 362.951 102.010 205.979 180.331 Missing 95.955 
20 134.365 303.892 250.160 115.900 123.025 50.203 209.900 30.520 91.971 144.763 44.088 115.339 
MEAN 146.501 530.696 282.437 261.583 251.432 134.495 272.532 169.067 135.584 216.252 175.449 142.203 
SD 63.343 202.269 95.518 125.616 109.014 59.122 111.599 104.954 52.844 160.795 89.265 70.316 
GEOM MEAN 133.763 498.758 267.288 234.807 231.0} I 121.837 252.164 140.278 126.287 171.831 145.618 125.858 
GEOM SD 1.564 1.427 1.409 1.613 1.519 1.603 1.508 1.918 1.479 2.078 2.045 1.694 
CV% 43.237 38.114 33.819 48.021 43.357 43.958 40.949 62.079 38.975 74.356 50.878 49.448 
SEM 14.532 46.404 21.913 28.818 25.010 13.564 25.602 24.078 12.123 36.889 21.040 16.132 
MIN 52.821 288.237 159.673 115.900 123.025 50.203 93.639 30.520 56.198 25.350 27.519 43.788 
MAX 294.874 1014.808 440.579 507.559 466.571 270.125 547.894 437.057 267.777 736.325 331.779 302.338 
MEDIAN 134.820 487.445 262.853 230.173 220.228 129.593 245.397 131.249 124.559 180.331 186.824 142.868 
N 19 19 19 19 19 19 19 19 19 19 18 19 
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FARMOVS 9/96 
ANDROSTERONE EXCRETION RATE ("g/llr) 
BENEMID 























GEOM MEAN 156.635 
























































































































































































































































24 to 30 h 30 to 36 h 
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FARMOYS 9/96 
URINARY CREATININE CONCENTRATIONS (mmo111) 
PLACEBO 






















GEOM MEAN 13.677 


























































































































































































































12 to 24 h 24 to 30 h 30 to 36 h 36 to 48 h 
17.12 16.95 20.92 20.26 
15.63 11.38 6.26 16.08 
14.19 16.01 9.76 7.45 
19.29 15.28 13.69 15.48 
7.38 7.36 13.91 17.82 
19.28 21.93 19.77 17.80 
8.16 10.64 10.06 15.35 
22.15 4.74 11.03 17.88 
12.58 7.19 4.32 11.27 
15.34 5.96 4.86 13.79 
20.47 17.30 6.54 3.10 
12.32 10.31 16.77 18.85 
5.67 12.98 10.43 14.71 
15.60 10.30 17.14 19.41 
14.75 12.49 14.46 10.05 
9.33 2.83 4.21 28.03 
16.93 7.18 16.02 8.55 
13.98 17.15 18.73 15.53 
15.39 12.80 7.24 12.25 
14.503 11.620 11.901 14.929 
4.479 5.016 5.432 5.504 
13.719 10.420 10.578 13.686 
1.439 1.675 1.683 1.614 
30.885 43.163 45.646 36.865 
1.028 1.151 1.246 1.263 
5.670 2.830 4.210 3.100 
22.150 21.930 20.920 28.030 
15.340 11.380 11.030 15.480 
19 19 19 19 
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FARMOVS 9/96 
URINARY CREATININE CONCENTRATIONS (mmol/I) 
BENEMID 
DOSE: 4 X 500 MG PROBENECID TA8LETS 






















GEOM MEAN 14.515 
GEOM SD 1.483 

























































































































































































































121024h 241030h 301036h 
10.75 9.21 11.50 
14.02 12.71 17.23 
16.51 17.17 17.55 
12.08 13.87 16.01 
13.61 11.90 16.35 
17.63 15.37 19.95 
11.14 15.93 16.67 
8.69 13.04 16.48 
10.05 3.56 9.97 
19.57 15.06 7.49 
8.34 23.35 9.87 
6.80 9.84 9.81 
15.41 11.34 11.51 
12.25 9.43 15.49 
13.99 13.36 10.22 
11.38 12.73 11.07 
5.80 10.30 12.14 
17.38 22.05 Missing 
10.79 11.74 10.37 
12.431 13.261 13.316 
3.763 4.495 3.600 
11.857 12.439 12.853 
1.384 1.486 1.318 
30.270 33.895 27.032 
0.863 1.031 0.848 
5.800 3.560 7.490 
19.570 23.350 19.950 
12.080 12.730 11.825 
19 19 18 
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FARMOVS 9/96 
URINARY ANDROSTERONE CONCENTRATION EXrRESSEIl PER MMOL CREATININE (I'g/mmol) 
PLACEDO 






















GEOM MEAN 261.599 
GEOM SD 1.413 
CV % 33.201 
SEM 21.051 
MIN 147.996 
MAX 467 .047 
MEDIAN 288.431 
N 19 
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FARMOVS 9/96 
URINAIIY ANDROSTERONE CONCENTRATION EXPRESSED PER MMOL CREATININE (flg/mmol) 
BENEMID 
DOSE: 4 X 500 MG PROBENECID TABLETS 
SUBJECT -12toOh o to I h I to 2 h 2 to 3 h 3 t04 h 4 to 6 h 6 to 8 h 8 to 12 h 12t024h 24 to 30 h 30 to 36 h 36 t048 h 
246.247 267.534 120.751 112.500 118.018 120.370 87.420 93.152 123.628 181.976 222.522 255.263 
2 203.735 268.447 99.187 82.883 84.884 100.585 103.715 114.544 130.029 190.165 200.058 199.177 
3 408.818 399.934 99.896 127.184 151.724 185.294 204.425 178.824 254.936 374.490 274.872 340.934 
4 384.783 544.091 167.757 181.295 209.603 209.370 235.837 229.169 284.189 336.410 499.563 522.618 
5 324.881 425.975 135.294 141.111 145.902 121.311 145.369 188.243 247.318 344.706 388.930 300.865 
6 315.599 364.274 179.197 158.222 170.677 160.923 166.821 200.132 241.010 338.061 331.830 331.725 
7 262.375 251.247 75.000 81.967 66.387 87.273 73.646 126.236 147.397 197.489 206.179 147.587 
8 167.143 248.512 176.558 192.171 208.191 202.657 113.552 194.531 130.840 170.245 177.124 164.150 
9 202.030 244.915 118.382 102.655 97.000 126.667 121.154 138.220 202.786 265.449 271.615 206.310 
11 259.909 271.406 83.478 91.525 92.982 90.972 103.542 115.651 136.689 199.801 245.394 250.322 
12 410.549 367.672 130.597 118.852 118.280 138.073 117.790 146.601 165.947 353.662 481.054 485.532 
13 180.853 197.698 41.456 73.864 110.219 131.982 95.007 110.825 168.529 280.386 274.516 246.388 
14 311.952 240.678 65.039 65.744 84.783 105.904 109.040 108.748 159.831 257.407 290.269 291.696 
15 332.406 445.520 186.224 127.419 127.715 133.753 147.225 194.460 264.898 466.596 116.850 230.946 
16 534.511 557.903 137.209 114.535 163.455 170.107 184.507 197.201 683.488 532.859 503.425 533.265 
17 264.545 267.184 185.714 Missing 81.290 108.421 132.836 172.875 201.406 340.456 120.687 227.464 
18 205.931 209.717 61.972 62.703 68.148 70.899 78.078 102.733 115.690 167.573 183.773 151.152 
19 346.610 341.053 106.962 96.454 111.321 115.135 167.879 195.830 213.291 371.837 Missing 378.784 
20 182.001 147.650 49.787 56.154 60.909 64.103 55.522 77.769 120.945 179.898 199.325 165.202 
MEAN 291.836 319022 116.866 110.402 119.552 128.621 128.598 151.881 210.150 292.077 277.110 285.757 
SO 97.143 114.018 47.141 39.355 45.006 41.328 47.017 45.271 126.850 105.282 120.751 120.606 
GEOMMEAN 277.461 300.958 106.834 104.018 111.971 122.402 120.692 145.136 189.086 274.798 253.837 264.289 
GEOMSO 1.384 1.419 1.578 1.429 1.450 1.387 1.448 1.372 1.534 1.433 1.542 1.493 
CV% 33.287 35.740 40.337 35.647 37.645 32.132 36.561 29.807 60.362 36.046 43.575 42.206 
SEM 22.286 26.158 10.815 9.276 10.325 9.481 10.786 10.386 29.101 24.153 28.461 27.669 
MIN 167.143 147.650 41.456 56.154 60.909 64.103 55.522 77.769 115.690 167.573 116.850 147.587 
MAX 534.511 557.903 186.224 192.171 209.603 209.370 235.837 229.169 683.488 532.859 503.425 533.265 
MEDIAN 264.545 268.447 118.382 107.577 111.321 121.311 117.790 146.601 168.529 280.386 258.504 250.322 
N 19 19 19 18 19 19 19 19 19 19 18 19 
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RAw DATA - PROBENECID 
FARMOVS 9/96 
PROBENECID CONCENTRATIONS ("g/ml) 
LLOQ = 0.061'g/ml 
BENEMID 
DOSE: 4 X 500 MG PROBENECID TABLETS 
SUUJECT o to I h I to 2 h 2 to 3 h 3 to 4 h 4 to 6 h 6 to 8 h 8 to 12 h 12 to 24 h 24 to 30 h 30 to 36 h 36 to 48 h 
I 24.760 99.090 32.650 27.640 39.400 99.210 189.830 145.150 215.240 226.770 193.770 
2 20.490 59.090 57.530 76.980 79.370 75.050 99.500 143.160 267.760 303.520 264.780 
3 32.860 472.790 76.290 37.350 22.730 24.060 71.330 454.660 378.410 140.800 73.730 
4 26.330 67.870 47.400 66.060 58.450 101.380 ' 188.870 170.570 184.590 170.920 37.570 
5 23.650 153.470 62.980 41.220 32.890 296.650 84 .910 425.470 91.140 206.500 24.240 
6 57.920 218.740 84.980 43.980 104.240 127.700 158.750 385.300 95.090 244.770 179.960 
7 39.150 36.410 38.150 40.740 56.420 114.380 84.300 181.440 295.000 294.730 49.660 
8 30.210 128.940 314.870 443 .210 471.970 386.010 21.690 271.320 456.210 503.590 224.180 
9 51.030 30.120 26.050 25.780 156.160 21.390 43.080 161.480 19.900 78.790 55.550 
11 24.680 26.650 31.640 33.360 46.870 39.490 203.140 337.000 87.960 85.010 184.220 
12 34.010 20.570 28.320 91.760 36.070 58.820 166.860 93.100 369.730 134.250 23.710 
13 49.860 53.960 61.070 47.980 82.300 116.930 138.180 131.570 89.920 196.140 100.420 
14 42.680 97.210 155.090 42.790 36.370 92.640 264.530 329.140 212.450 157.500 278.370 
15 34.430 73.950 92.960 82.550 79.290 306.060 259.110 272.910 79.960 179.960 63.270 
16 34.320 36.820 52.820 82.130 93.200 29.020 111.060 660.260 115.830 63.100 47.940 
." -, '1"" 56.620 30.280 42.640 24.490 45.340 101.980 249.610 277.250 156.700 164.690 "" 18 :;: :::! 210 51.410 62.990 44.720 37.400 125.970 78.880 71.260 165.090 56.910 45.610 :u n:t I? ;"1 __ • 670 143.420 89.680 115.790 207.290 53.320 80.060 287.190 255.460 Missing 82.260 
m ('J W, . ' :r'l .040 402.860 44.450 34.660 35.050 170.720 393.850 94.900 245.890 174.950 81.730 
"" :~ V I m P't .... ~ 
-,.. c,-, ;,' .~: ii4 
89.472 120.218 256.078 205.415 114.508 ~AN:"_ _, :..: ~ 6.981 117.368 73.168 74.807 144.206 187.495 i \;'* " 124.501 66.294 92.546 104.009 102.819 91.052 151.050 118.741 106.366 83.392 
. * EAN . :1 0.487 79.143 58.364 55.622 62.855 87.286 118.318 217.102 166.143 162.314 87.049 
M'SD .; ...... f- 677 2.391 1.870 1.924 2.169 2.304 1.982 1.827 2.127 1.758 2.193 
% ~ UF o.588 106.078 90.605 123.713 116.248 85.527 63.140 58.986 57.806 56.730 72.826 
SEM -< 1.285 28.563 15.209 21.232 23.861 23.588 20.889 34.653 27.241 25.071 19.132 , 
MIN -:10.490 20.570 26.050 25.780 22.730 21.390 21.690 71.260 19.900 56.910 23.710 
MAX 133.040 472.790 314.870 443.210 471.970 386.010 393.850 660.260 456.210 503.590 278 .370 
MEOIAN 34.430 67.870 57.530 43.980 56.420 99.210 111.060 249.610 212.450 172.935 81. 730 
N 19 19 19 19 19 19 19 19 19 18 19 
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FARMOVS 9/96 
FIIACTIONAL PIHlUI:NECIIl EXCIIETION (,Ig) 
LLOQ ~ 0.06,lg/ml 
DENEMID 
DOSE: 4 X 500 MG l'II0UENECIJ) TABLETS 
SUBJECT 010 I h I 102 h 2 to 3 h 3104 h 4106 h 6108 h 810 12 h 121024h 24 10 30 h 301036 h 361048 h 
I 3103.171 12251.488 14753.556 18932.018 30942.396 14087.820 52043.793 85101.445 55893.523 113441.693 82272.804 
2 6339.40 I 31926.327 23018.904 22947.738 26061.140 16571.040 27925.670 70973.002 53359.213 51300.950 129596.571 
3 1687.032 34750.065 20468.607 21487.082 26996.648 23225.840 25598.197 187897.338 65741.169 46861.056 43876.723 
4 2838.374 22812.464 10984.950 24160.784 7357.686 17437.360 30479.841 50215.808 90079.920 73666.520 22537.492 
5 3329.211 20649.389 26022.706 12585.290 7465.701 65856.300 25753.203 220818.930 31766.847 45630.305 24349.807 
6 6525.267 32200.715 22840.075 17531.308 35983.648 20910.875 55743.475 148590.945 22968.039 56456.201 54283.134 
7 3858.233 13667.222 17316.667 20406.666 16033.436 42731.224 26314.245 127488.816 73452.050 81254.114 31389.093 
8 4914.563 19320.370 22793.439 27705.057 47480.182 38601.000 28795.427 156304.739 96561.409 74002.551 69894.840 
9 7204.926 18643.075 18217.026 20413.635 229369.370 21914.483 28770.978 160746.881 15473.842 21872.104 25115.822 
II 3145.466 20059.988 21351.305 23042.419 16764.930 3396.140 55355.650 129893.280 24452.000 33842.48 1 66483.156 
12 8802.468 8154.977 12490.536 39061.314 12104.731 13736.235 48823.236 68614.700 50882.243 38449.200 12009.115 
13 5692.018 6313.320 13845.790 21736.859 52342.800 20723.504 54615.645 118260.379 20524.240 26914.331 58374.146 
14 2131.012 6414.888 7816.536 10103.575 7283.456 15442.162 69997.283 144479.294 39764.267 26896.275 67348 .838 
15 8056.620 28260.732 34000.120 21445.665 25138.895 47408.694 83767.672 158814.516 51568.603 52130.813 42265.625 
16 5374.169 10219.391 25792.006 15666.298 34787.832 17126.443 41664.159 170347.080 29752094 22274.300 31403.576 
17 12338.608 29486.564 16472.320 12067.120 12103.203 43077.081 48126.402 100660.225 69331.908 24138.068 60316.066 
18 8604.509 28265.732 21747.927 19484.504 16260.772 10959.390 30004.374 33299.085 123918.205 7368.707 34361.206 
19 15758.372 19949.722 13999.945 9884.992 24688.239 18690.260 15872.696 133391.139 53265.965 Missing 4621.367 
20 10653.843 41937.726 16834.104 25938.504 8264.790 22941.354 65197.929 67251.834 22262.881 58555.765 40350.918 
MEAN 6334.593 21330.745 18987.71 1 20242.149 33548.940 24991.432 42886.835 122797.339 52158.864 47503.080 47413.174 
SD 3720.338 10277.978 6221.757 6848.391 49248.834 15421.265 18331.512 50113.114 29289.729 26215.298 28939.052 
GEOMMEAN 5363.882 18624.677 17985.355 19150.962 21483.347 20848.716 39243.406 111124.702 44674.764 40269.206 38352.994 
GEOM SD 1.836 1.771 1.417 1.418 2.341 1.923 1.552 1.639 1.797 1.895 2.120 
CV% 58.730 48.184 32.767 33.832 146.797 61.706 42.744 40.810 56.155 55.187 61.036 
SEM 853 .504 2357.930 1427.369 1571.129 11298.457 3537.881 4205.537 11496.737 6719.525 6179.005 6639.074 
MIN 1687.032 6313.320 7816.536 9884.992 7283.456 3396.140 15872.696 33299.085 15473.842 7368.707 4621.367 
MAX 15758.372 41937.726 34000. 120 39061.3 14 229369.370 65856.300 83767.672 220818.930 123918.205 113441.693 129596.571 
MEDIAN 5692.018 20059.988 18217.026 20413.635 24688.239 20723.504 41664.159 129893.280 51568.603 46245.681 42265 .625 
N 19 19 19 19 19 19 19 19 19 18 19 
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FARMOVS 9/96 
CUMULATIVE PROBENECID EXCRETION (fIg) 
LLOQ ~ 0.0611g/ml 
DENEMID 
DOSE: 4 X 500 MG I'ROBENECID TABLETS 
SUIlJECT o to I h I to 2 h 2 to 3 h 3 to 4 h 4 to 6 h 6 to 8 h 8 to 12 h 12 to 24 h 24 to 30 h 30 to 36 h 36 to 48 h 
I 3103.171 15354.658 30108.214 49040.232 79982.628 94070.448 146114.241 231215.686 287109.209 400550.901 482823.706 
2 6339.401 38265.728 61284.632 84232.370 110293.509 126864.549 154790.219 225763.221 279 122.434 330423.384 460019.955 
3 1687.032 36437.097 56905.704 78392.786 105389.434 1286 15.274 154213.471 342 110.809 40785 1.979 454713.035 498589.758 
4 2838.374 25650.838 36635.788 60796.573 68154.259 8559 1.619 116071.459 166287.267 256367.187 330033.707 352571.199 
5 3329.211 23978.599 50001.305 62586.596 70052.297 135908.597 161661.800 382480.730 414247.577 459877.882 484227.689 
6 6525.267 38725.983 61566.057 79097.365 115081.013 135991.888 191735.363 340326.308 363294.346 419750.547 474033.681 
7 3858.233 17525.454 34842.121 55248.787 71282.222 114013.447 140327.692 267816.508 341268.558 422522.671 453911.764 
8 49 14.563 24234.932 47028 .372 74733.429 122213.611 160814.611 189610.038 3459 14.777 442476.185 516478.736 586373.576 
9 7204.926 25848.00 1 44065.026 64478.662 293848.03 1 315762.514 344533.492 505280.373 520754.215 542626.319 567742.140 
II 3145.466 23205.454 44556.759 67599.178 84364.108 87760.248 143115.898 273009.178 297461.179 331303.660 397786.816 
12 8802.468 16957.445 29447 .98 1 68509.295 80614.026 94350.261 143173.497 211788.197 262670.440 301119.640 313128.755 
13 5692.018 12005.338 25851.128 47587.987 99930:787 120654.291 175269.936 293530.3 15 314054.555 340968.886 399343.032 
14 2131.012 8545.900 16362.436 26466.01 1 33749.467 49191.629 119188.912 263668.207 303432.473 330328.748 397677.586 
15 8056.620 363 17.352 70317.472 9 1763.137 116902.031 164310.725 248078.397 406892.913 45846 1.516 510592.329 552857.954 
16 5374.169 15593.560 41385 .566 57051.863 91839.695 108966.139 150630.298 320977.378 350729.471 373003.771 404407.348 
17 12338.608 4 1825.171 58297.491 70364.611 82467.814 125544.895 173671.296 27433 1.521 343663.429 36780 1.497 428117.562 
18 8604.509 36870.24 1 58618.168 78 102.672 94363.444 105322.834 135327.208 168626.294 292544.499 299913.206 334274.411 
19 15758.372 35708.094 49708 .038 59593.031 84281.270 102971.529 11 8844.225 252235.364 305501.329 305501.329 310122.696 
20 10653.843 52591.569 69425.673 95364. 177 103628.967 126570.321 191768.250 259020.084 281282.965 339838.730 380 189.648 
MEAN 6334.593 27665.338 46653.049 66895. 198 100444.138 125435.569 168322.405 291119.744 343278.608 388281.525 435694.699 
SD 3720.338 11 869.424 15125.964 16476.045 51384.562 53398.799 53231.473 83575.082 73778.692 77427.877 82023.345 
GEOMMEAN 5363.882 25024.669 43926.560 64592.8 11 92314.997 117471.566 162253.603 280292.734 336430.426 381406.342 428371.686 
GEOMSD 1.836 1.620 1.459 1.336 1.495 1.433 1.301 1.327 1.224 1.209 1.209 
CV% 58.730 42.904 32.422 24.630 51.157 42.571 31.625 28.708 21.492 19.941 18.826 
SEM 853.504 2723.033 3470. 134 3779.864 11788.427 12250.525 12212.137 19173.439 16925.993 17763.173 18817.446 
MtN 1687.032 8545.900 16362.436 26466.011 33749.467 49191.629 116071.459 166287.267 256367.187 299913.206 310122.696 
MAX 15758.372 52591.569 703 17.472 95364.177 293848.031 315762.514 344533.492 505280.373 520754.215 542626.319 586373.576 
MEDtAN 5692.018 25650.838 47028.372 67599. 178 91839.695 120654.291 154213.471 273009.178 314054.555 367801.497 428117.562 
N 19 19 19 19 19 19 19 19 19 19 19 
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FARMOVS 9196 
CtJMULATIVE i'RODENECII) EXCIIETION As i'ERCENTAGE OF DOSE (%) 
LLOQ = 0.06flg/ml 
BENEMID 
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F AHMOVS 9/96 
PHOBENECIf) EXCRETION RATE ("g/h) 
LLOQ = 0.06/'g/ml 
BENEMID 
DOSE: 4 X 500 MG PRODENECIIl TABLETS 
SUBJECT 010 I h I 102 h 2 to 3 h 3 to 4 h 4 to 6 h 6108 h 8 to 12 h 12 to 24 h 241030 h 301036 h 361048 h 
3103.171 12251.488 14753.556 18932.018 15471.198 7043.910 13010.948 7091.787 9315.587 18906.949 6856.067 
2 6339.401 31926.327 23018.904 22947.738 13030.570 8285.520 6981.418 5914.417 8893.202 8550.158 10799.714 
3 1687.032 34750.065 20468.607 21487.082 13498.324 11612.920 6399.549 15658.112 10956.862 7810.176 3656.394 
4 2838.374 22812.464 10984.950 24160.784 3678.843 8718.680 7619.960 4184.651 15013.320 12277.753 1878.124 
5 3329.211 20649.389 26022.706 12585.290 3732.851 32928.150 6438.30 I 18401.578 5294.475 7605.051 2029.151 
6 6525.267 32200.715 22840.075 17531.308 17991.824 10455.438 13935.869 12382.579 3828.006 9409.367 4523.595 
7 3858.233 13667.222 17316.667 20406.666 8016.718 21365.612 6578.561 10624.068 12242.008 13542.352 2615.758 
8 4914.563 19320.370 22793.439 27705.057 23740.091 19300.500 7198.857 13025 .395 16093.568 12333.758 5824.570 
9 7204.926 18643.075 18217.026 20413.635 114684.685 10957.241 7192.745 13395.573 2578.974 3645.351 2092.985 
II 3145.466 20059.988 21351.305 23042.419 8382.465 1698.070 13838.913 10824.440 4075.333 5640.414 5540.263 
12 8802.468 8154.977 12490.536 39061.314 6052.366 6868.117 12205.809 5717.892 8480.374 6408.200 1000.760 
13 5692018 6313.320 13845.790 21736.859 26171.400 10361.752 13653.911 9855.032 3420.707 4485.722 4864.512 
14 2131.012 6414.888 7816.536 10103.575 3641.728 7721.081 17499.321 12039.941 6627.378 4482.713 5612.403 
15 8056.620 28260.732 34000.120 21445.665 12569.447 23704.347 20941.918 13234.543 8594.767 8688.469 3522.135 
16 5374.169 10219.391 25792.006 15666.298 17393.916 8563.222 10416.040 14195.590 4958.682 3712.383 2616.965 
17 12338.608 29486.564 16472.320 12067.120 6051.601 21538.540 12031.600 8388.352 11555.318 4023.011 5026.339 
18 8604.509 28265 .732 21747.927 19484.504 8130.386 5479.695 7501.094 2774.924 20653.034 1228.118 2863.434 
19 15758.372 19949.722 13999.945 9884.992 12344.120 9345.130 3968.174 11115.928 8877.661 Missing 385.114 
20 10653.843 41937.726 16834.104 25938.504 4132.395 11470.677 16299.482 5604.320 371 0.480 9759.294 3362.577 
MEAN 6334.593 21330.745 18987.711 20242.149 16774.470 12495.716 10721.709 10233.112 8693.144 7917.180 3951.098 
SD 3720.338 10277.978 6221.757 6848.391 24624.417 7710.633 4582.878 4176.093 4881.622 4369.216 2411.588 
GEOMMEAN 5363.882 18624.677 17985.355 19150.962 10741.674 10424.358 9810.852 9260.392 7445.794 6711.534 3196.083 
GEOM SD 1.836 1.771 1.417 1.418 2.341 1.923 1.552 1.639 1.797 1.895 2.120 
CV% 58.730 48.184 32.767 33.832 146.797 61.706 42.744 40.810 56.155 55.187 61.036 
SEM 853.504 2357.930 1427.369 1571.129 5649.229 1768.940 1051.384 958.061 1119.921 1029.834 553.256 
MIN 1687.032 6313.320 7816.536 9884.992 3641.728 1698.070 3968.174 2774.924 2578.974 1228.118 385.114 
MAX 15758.372 41937.726 34000.120 39061.314 114684.685 32928.150 20941.918 18401.578 20653.034 18906.949 10799.714 
MEDIAN 5692.018 20059.988 18217.026 20413.635 12344.120 10361.752 10416.040 10824.440 8594.767 7707.613 3522.135 
N 19 19 19 19 19 19 19 19 19 18 19 
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F ARMOVS 9/96 
PROBENECID CONCENTRATION EXPRESSED PER MMOL CREATININE (flg/mmol) 
LLOQ ~ 0.06f1g/ml 
BENE MID 
DOSE: 4 X 500 MG PROBENECIIl TABLETS 
SUBJECT ·12100 h 010 I h 1I02h 2103 h 3104 h 4106 h 6108 h 810 12 h 121024h 24 10 30 h 301036 h 361048 h 
2220.628 19583.004 22673.611 24900.901 24320.988 15797.771 17807.692 13502.326 23370.250 19719.130 13074.899 
2 4973.301 48040.650 51828.829 44755.814 46415.205 11617.647 9979.940 10211.127 21066.876 17615.786 12822.276 
3 2157.584 49095.535 37033.981 32198.276 22284.314 21292.035 11988.235 27538.462 22039.022 8022.792 5837.688 
4 1819.627 31714.953 34100.719 21874.172 9442.649 12485.222 10394.606 14120.033 13308.580 10675.828 3345.503 
5 2096.631 31129.817 34988.889 33786.885 10783.607 30868.887 10508.663 31261.572 7658.824 12629.969 3492.795 
6 4724.307 39916.058 37768.889 33067.669 32073.846 14814.385 20915.679 21854.793 6186.727 12269.173 7820.947 
7 2568.898 28445.313 31270.492 34235.294 20516.364 20646.209 16026.616 16287.253 18518.519 17680.264 3745.098 
8 4495.536 38261.128 56026.690 54182.152 50156.217 42186.885 16945.313 31222.094 34985.429 30557.646 12177.078 
9 4805.085 22147.059 23053.097 25780.000 148723.810 13711.538 11277.487 16067.662 5589.888 7902.708 4075.569 
11 1960.286 23173.913 26813.559 29263.158 32548.611 8227.083 17186.125 17220.235 5840.637 11349.800 7416.264 
12 5696.817 15350.746 23213.115 49333.333 16545.872 7927.224 20625.464 11163.070 15834.261 13601.824 10089.362 
13 3587.050 8537.975 17349.432 35021.898 37072.072 15780.027 18698.241 19348.529 9138.211 19993.884 6363.752 
14 3807.315 12494.859 17888.120 18604.348 13420.664 17446.328 24358.195 21358.858 18734.568 13683.753 19264.360 
15 4975.434 37729.592 49978.495 30917.603 16622.642 26136.635 23534.060 22278.367 8479.321 11617.818 4399.861 
16 5215.805 28542.636 30709.302 27285.714 33167.260 20436.620 14129.771 47195.139 8669.910 6174.168 4906.858 
17 8665.766 11234.127 21323.944 27509.677 25778 .947 22557.214 18441.230 21934.095 21779.262 14155.375 8238.619 
18 5696.356 36204.225 34048.649 33125.926 19788.360 10005.560 9798.758 12286.207 16028.155 4687.809 4043.440 
19 2156.573 30257.384 21200.946 21847.170 23238.789 8078.788 6546.198 16524.166 11585.488 Missing 5000.608 
20 9475.783 85714.894 34192.308 31509.091 14978.632 10359.223 31839.127 8795.181 20944.634 16870.781 4034.057 
MEAN 4268.357 31451.256 31866.477 32063.1 Hi 31467.308 17388.173 16368.495 20008.904 15250.451 13844.917 7376.265 
SD 2181.861 17604.388 11284.305 9129.706 30553.140 8761.393 6266.434 9275.469 7815.579 6073.016 4323.653 
GEOMMEAN 3782.777 27265.912 30097.293 30939.060 24871.292 15627.070 15244.578 18309.402 13356.174 12628.830 6421.320 
GEOM SD 1.661 1.758 1.412 1.312 1.880 1.597 1.484 1.530 1.723 1.573 1.688 
CV% 51.117 55.974 35.411 28.474 97.095 50.387 38.284 46.357 51.248 43.865 58.616 
SEM 500.553 4038.724 2588.797 2094.498 7009.371 2010.001 1437.619 2127.938 1793.017 1431.424 991.914 
MIN 1819.627 8537.975 17349.432 18604.348 9442.649 7927.224 6546.198 8795.181 5589.888 4687.809 3345.503 
MAX 9475.783 85714.894 56026.690 54182.152 148723.810 42186.885 31839.127 47195.139 34985.429 30557.646 19264.360 
MEDIAN 4495.536 30257.384 31270.492 31509.091 23238.789 15780.027 16945.313 17220.235 15834.261 13115.897 5837.688 
N 19 19 19 19 19 19 19 19 19 . 18 19 
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